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A B S T R A C T
Background
The aetiology of preterm birth is complex and there is evidence that subclinical genital tract infection influences preterm labour in
some women but the role of prophylactic antibiotic treatment in the management of preterm labour is controversial. Since rupture
of the membranes is an important factor in the progression of preterm labour, it is important to see if the routine administration of
antibiotics confers any benefit or causes harm, prior to membrane rupture.
Objectives
To assess the effects of prophylactic antibiotics administered to women in preterm labour with intact membranes, on maternal and
neonatal outcomes.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (31 August 2013).
Selection criteria
Randomised trials that compared antibiotic treatment with placebo or no treatment for women in preterm labour (between 20 and 36
weeks’ gestation) with intact membranes.
Data collection and analysis
Two review authors independently assessed trial eligibility, and undertook quality assessment and data extraction. We contacted study
authors for additional information. Results are presented using risk ratio (RR) for categorical data and mean difference (MD) for data
measured on a continuous scale with their respective 95% confidence intervals (CI). The number needed to treat to benefit (NNTB)
and the number needed to treat to harm (NNTH) was calculated where appropriate.
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Main results
In this update (2013), with the addition of three trials (305 women), the large ORACLE II 2001 trial continues to dominate the
results of this review. This review now includes a total of 14 studies randomising 7837 women. No significant difference was shown in
perinatal or infant mortality for infants of women allocated to any prophylactic antibiotics compared with no antibiotics. However, an
increase in neonatal deaths was shown for infants of women receiving any prophylactic antibiotics when compared with placebo (RR
1.57, 95% CI 1.03 to 2.40; NNTH 149, 95% CI 2500 to 61). No reduction in preterm birth or other clinically important short-term
outcomes for the infant were shown.
Long-term child outcomes to seven years of age were available for infants in the UK enrolled in the ORACLE II trial. Comparing any
antibiotics with placebo, a marginally non-statistically significant increase was shown in any functional impairment (RR 1.10, 95% CI
0.99 to 1.23) and cerebral palsy (CP) (RR 1.82, 95% CI 0.99 to 3.34). In subgroup analysis, CP was statistically significantly increased
for infants of women allocated to macrolide and beta-lactam antibiotics combined compared with placebo (RR 2.83, 95% CI 1.02 to
7.88; NNTH 35, 95% CI 333 to 9).
Further, exposure to any macrolide antibiotics (including erythromycin alone or erythromycin plus co-amoxiclav) versus no macrolide
antibiotics (including placebo and co-amoxiclav alone) was shown to increase neonatal death (RR 1.52, 95% CI 1.05 to 2.19; NNTH
139, 95% CI 1429 to 61), any functional impairment (RR 1.11, 95% CI 1.01 to 1.20; NNTH 24, 95% CI 263 to 13) and CP (RR
1.90, 95% CI 1.20 to 3.01; NNTH 64, 95% CI 286 to 29). Exposure to any beta-lactam (beta-lactam alone or in combination with
macrolide antibiotics) versus no beta-lactam antibiotics resulted in more neonatal deaths (RR 1.51, 95% CI 1.06 to 2.15; NNTH 143,
95% CI 1250 to 63) and CP (RR 1.67, 95% CI 1.06 to 2.61; NNTH 79, 95% CI 909 to 33), however no difference was shown in
functional impairment.
Maternal infection was reduced with the use of any prophylactic antibiotics compared with placebo (RR 0.74, 95% CI 0.63 to 0.86;
NNTB 34, 95% CI 24 to 63) and any beta-lactam compared with no beta-lactam antibiotics (RR 0.80, 95% CI 0.69 to 0.92; NNTB
47, 95% CI 31 to 119). However, caution should be exercised with this finding due to the possibility of bias shown by funnel plot
asymmetry. Any beta-lactam compared with no beta-lactam antibiotics was associated with an increase in maternal adverse drug reaction
(RR 1.61, 95% CI 1.02 to 2.54; NNTH 17, 95% CI 526 to 7).
Authors’ conclusions
This review did not demonstrate any benefit in important neonatal outcomes with the use of prophylactic antibiotics for women in
preterm labour with intact membranes, although maternal infection may be reduced. Of concern, is the finding of short- and longer-
term harm for children of mothers exposed to antibiotics. The evidence supports not giving antibiotics routinely to women in preterm
labour with intact membranes in the absence of overt signs of infection.
Further research is required to develop sensitive markers of subclinical infection for women in preterm labour with intact membranes,
as this is a group that might benefit from future novel interventions, including new modalities of antibiotic therapy. The results of
this review demonstrate the need for future trials in the area of preterm birth to include assessment of long-term neurodevelopmental
outcome.
P L A I N L A N G U A G E S U M M A R Y
Prophylactic antibiotics for inhibiting preterm labour in women whose membranes are still intact
We found no benefit for the use of antibiotics for women going into labour too early, with their membranes still intact.
Maternal infection in the cervix or uterusmay trigger preterm labour even if the infection does not cause symptoms (low grade infection).
Preterm babies can have a range of complications, which often require admission to a neonatal intensive care unit, for example, because
of breathing problems. Complications of being born early may result in death or longer-term disability such as chronic lung disease or
cerebral palsy. Our systematic review of randomised trials, which included a total of 14 studies randomising 7837 women in preterm
labour at amean gestational age of 30 to 32weeks compared routine administration of antibiotics beforemembrane rupture with placebo
or no treatment for women without signs of infection. While antibiotics reduced the number of women who developed infections, they
did not improve outcomes for the infant in terms of birth before 36 to 37 weeks, perinatal deaths or admission to neonatal intensive
care or special care with serious illness. The review also found that antibiotic therapy was associated with an increase in neonatal deaths,
functional impairment and cerebral palsy at seven years of age. The results of this review supports not giving antibiotics to women in
threatened preterm labour with intact membranes who did not have clear signs of infection.
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B A C K G R O U N D
Preterm birth is a major contributor to the burden of perinatal
mortality and morbidity (Lawn 2010). The rate of preterm birth
has been increasing (Norman 2009;Tracy 2007), in both high- and
low-middle income countries. For example, by 2005 it had risen in
the USA from 9.5% in 1981 to 12.7% by 2005 (Hamilton 2006).
Whilst increases in obstetric intervention have been implicated in
rising rates of preterm birth (Henderson 2012; Norman 2009),
the greatest proportion of pretermbirth occurs as a consequence of
spontaneous preterm labour in 40% to 45% of cases (Henderson
2012).
Little progress has been made over the last three decades in reduc-
ing the incidence of preterm birth despite a wide range of thera-
peutic interventions (Moutquin 1996; Muglia 2010). The initi-
ation of parturition in humans is complex and still incompletely
understood (Smith 2007). Of the pathways that play a role in the
onset of labour, the three components that appear to be central to
initiation and progression of labour are progesterone withdrawal,
increasing oxytocin circulation and decidual activation (Romero
2006). Of these, decidual activation would seem to be the main
pathway by which infection would play a role in preterm labour.
Such mechanisms may be acted upon directly though bacterial
stimulation of prostaglandin synthesis or indirectly through a
range of microbial endotoxins and inflammatory mediators (Bejar
1981). Infection may account for approximately 25% to 40% of
spontaneous preterm birth (Goldenberg 2000). The presence of
Ureaplasma urealyticum and Mycoplasma spp. have been detected
in the amniotic fluid of women experiencing preterm birth (Yoon
2003). The presence of intra amniotic infection occurs more fre-
quently with earlier gestational ages of preterm birth. The pres-
ence of the fetal inflammatory response is linked both to the on-
set of preterm labour and associated with an increased incidence
of longer-term morbidity such as cerebral palsy and chronic lung
disease (Yoon 2000).
While the contribution of subclinical genital tract infection to
the aetiology of preterm birth is recognised, the role of antibiotic
treatment in the management of preterm labour with intact mem-
branes remains uncertain. While colonisation or the presence of
bacteria, generally of low virulence, in the chorioamnion is com-
mon, this alone is insufficient to cause an inflammatory response
to initiate preterm labour. As preterm prelabour rupture of the
membranes has a major impact on the progression of preterm
labour, we considered it important to assess the potential benefit
of commencing prophylactic antibiotic therapy (usually given in
addition to tocolysis) prior to membrane rupture.
It has also been hypothesised that the type of antibiotic may be
important. Bacteriostatic antibiotics such as erythromycin have
theoretical advantages over the beta-lactam antibiotics (penicillins,
cephalosporins). The beta-lactams by destroying bacteria, release
endotoxins which may increase local inflammatory mediators and
adversely impact preterm birth (McGregor 1997). However, it
has been suggested that erythromycin, through effects on the car-
diovascular system, may lead to cerebral ischaemic events (Kallen
2005). Furthermore, the anaerobic organisms responsible for bac-
terial vaginosis (especially Bacteroides and Mobiluncus spp.) have
been implicated in the aetiology of preterm labour. Antibiotics ac-
tive against anaerobic organisms (such as clindamycin andmetron-
idazole) may be more effective in prolonging gestation, but only
if such organisms are present (Hauth 1995). Other genital tract
infections such as trichomonas, chlamydia and gonorrhoea have
been associated with an increased risk of preterm birth, although
only when there is evidence of a maternal immune response in
some instances (Sweet 1987).
This review examines the role of prophylactic antibiotics given
to women in preterm labour with intact membranes. The use
of antibiotics for treatment of preterm rupture of membranes is
addressed in another review (Kenyon 2010).
O B J E C T I V E S
To assess the effects of prophylactic antibiotics administered to
women in preterm labour with intact membranes on maternal,
neonatal and longer-term outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished randomised trials that compared
outcomes for women and/or babies when prophylactic antibiotics
were used in the routinemanagement of preterm labourwith intact
membranes, with outcomes for controls (placebo or no treatment).
Trials utilising a quasi-randomised method of allocation and cross-
over randomised trials were excluded.
Types of participants
Women thought to be in preterm labour with intact membranes
between 20 and 36 completed weeks of gestation. The diagnosis
of preterm labour will be as defined by study investigators. This
reflects usual clinical practice, strengthening the generalisability of
the findings.
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Types of interventions
Antibiotics administered either intravenously or orally in theman-
agement of preterm labour with intact membranes compared with
no antibiotics (placebo or no treatment).
Types of outcome measures
Primary outcomes
For the infant/child
• Death (fetal, neonatal, or later death up to the time of
follow-up).
• Major long-term infant neurosensory impairment.
• Death or major long-term infant neurosensory impairment.
For the woman
• Serious adverse outcome related to antibiotic treatment
(respiratory arrest, cardiac arrest, death).
Secondary outcomes
For the infant/child
• Interval between randomisation and birth.
• Birth within 48 hours of randomisation.
• Birth within seven days of randomisation.
• Birth prior to 37 completed weeks.
• Birth prior to 34 completed weeks.
• Birth prior to 28 completed weeks.
• Gestational age at birth.
• Birthweight.
• Perinatal mortality
• Stillbirth.
• Neonatal death.
• Apgar score of less than seven at five minutes.
• Neonatal sepsis.
• Duration of mechanical ventilation.
• Respiratory distress syndrome.
• Necrotising enterocolitis.
• Retinopathy of prematurity (all stages).
• Retinopathy of prematurity (stages III and IV).
• Intraventricular haemorrhage (all grades).
• Intraventricular haemorrhage (grades 3 and 4).
• Cerebral cystic lesions (periventricular leukomalacia,
porencephalic cysts).
• Chronic lung disease (infant receiving any respiratory
support (supplemental oxygen or any form of assisted
ventilation) for a chronic pulmonary disorder (i) on the day they
reached 36 weeks’ post menstrual age, and (ii) at 28 days
postnatal age).
• Long-term neurosensory impairment (defined as moderate
or severe cerebral palsy as defined by trialists; moderate or severe
neurological impairment: developmental delay or intellectual
impairment - developmental quotient or intelligence quotient
less than two standard deviations (SD) below the mean; legal
blindness; sensorineural deafness requiring hearing aids).
For the woman
• Maternal adverse drug reaction.
• Maternal infection - chorioamnionitis/amnionitis.
• Postpartum pyrexia.
• Adverse drug reaction requiring cessation of treatment.
• Admission to intensive care.
• Maternal death.
Health services use
• Length of maternal postnatal hospital stay.
• Length of neonatal postnatal hospital stay.
In this update, primary and secondary outcomes have been de-
fined. Additional outcomes measures are included as primary out-
comes. For the woman these are: serious adverse outcome related
to antibiotic treatment (respiratory arrest, cardiac arrest, death);
admission to intensive care; and maternal death; and for the in-
fant/child, a composite measure of death (fetal, neonatal, or later
death up to the time of follow-up) or major long-term infant neu-
rosensory impairment. Further, the list of outcomes measures in-
cluded in subgroup analyses are now restricted to those that are
considered to be most clinically important as defined above.
Search methods for identification of studies
Electronic searches
We contacted the Trials Search Co-ordinator to search the
Cochrane Pregnancy and Childbirth Group’s Trials Register (31
August 2013).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of Embase;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
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Details of the search strategies for CENTRAL, MEDLINE and
Embase, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group. Trials identified through the searching ac-
tivities described above are each assigned to a review topic (or top-
ics). The Trials Search Co-ordinator searches the register for each
review using the topic list rather than keywords.
We did not apply any language restrictions.
Data collection and analysis
For the methods used in the previous version of this review, see
Appendix 1. For this update, we used the following methods when
assessing the reports identified in the previous version and in the
updated search.
Selection of studies
At least two review authors (V Flenady, G Hawley and O Stock)
independently assessed for inclusion all the potential studies we
identified as a result of the search strategy. We resolved any dis-
agreement through discussion or, if required, we consulted a third
person.
Data extraction and management
The review authors used the standard methods of The Cochrane
Collaboration and considered all potential trials for inclusion.
Evaluation of methodological quality and data extraction were un-
dertaken independently by at least two review authors (V Flenady,
G Hawley and O Stock) in this update, as described in Higgins
2011.
We resolved discrepancies through discussion. We entered data
into Review Manager software (RevMan 2012) and checked for
accuracy.
When information was unclear, we attempted to contact authors
of the original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We resolved
any disagreement by discussion or by involving a third author.
(1) Random sequence generation (checking for possible
selection bias)
Wedescribed for each included study themethods used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the methods as:
• low risk of bias (any truly random process, e.g. random
number table;computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth;hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to conceal
the allocation sequence and determined whether intervention al-
location could have been foreseen in advance of, or during recruit-
ment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3) Blinding (checking for possible performance bias)
We described for each included study, the methods used to blind
study participants and personnel from knowledge of which in-
tervention a participant received. We provided information on
whether the intended blinding was effective. Where blinding was
not possible, we assessed whether the lack of blinding was likely to
have introduced bias. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study and for each outcome or
class of outcomes the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported, the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported or was supplied by the
trial authors, we included missing data in the analyses which we
undertook.
We assessed the methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
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substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how the possibility of se-
lective outcome reporting bias was examined by us and what we
found. We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other sources of bias
We described for each included study any important concerns we
had about other possible sources of bias. We assessed whether each
study was free of other problems that could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). With
reference to (1) to (6) above, we assessed the likely magnitude and
direction of the bias and whether we considered it is likely to im-
pact on the findings. We planned to explore the impact of the level
of bias through undertaking sensitivity analyses- see Sensitivity
analysis. However, this was not required due to the generally high
quality of the included studies.
Measures of treatment effect
Dichotomous data
For dichotomous data, we present results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we used the mean difference as outcomes
were measured in the same way between trials.
Unit of analysis issues
Multiarm studies
For the subgroup comparisons undertaken, to avoid double count-
ing, we divided out data from the shared group approximately
evenly among the comparisons as described in theCochrane Hand-
book 16.5.4 (Higgins 2011). This was undertaken in the subgroup
analyses for the ORACLE II trial (Kenyon 2001a).
Multiple pregnancy
The analysis in this review involves multiple pregnancies, there-
fore, wherever possible, analyses should be adjusted for cluster-
ing to take into account the non-independence of babies from
the same pregnancy (Gates 2004). Treating babies from multiple
pregnancies as if they are independent, when they are more likely
to have similar outcomes than babies from different pregnancies,
will overestimate the sample size and give confidence intervals
that are too narrow. Each woman can be considered a cluster in
multiple pregnancy, with the number of individuals in the cluster
being equal to the number of fetuses in her pregnancy. Analysis
using cluster trial methods allows calculation of relative risk and
adjustment of confidence \intervals. Usually this will mean that
the confidence intervals get wider. Although this may make little
difference to the conclusion of a trial, it avoids misleading results
in those trials where the difference may be substantial.
We planned to adjust for clustering in the analyses, wherever pos-
sible, and to use the inverse variance method for adjusted analyses,
as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). However, due to insufficient infor-
mation in the included trials, we were not able to adjust our anal-
yses. In future updates, if possible, we will adjust for clustering in
the analyses. The largest trial, Kenyon 2001a, reported only one
neonatal outcome in a multiple pregnancy (the worst outcome)
where more than one outcome was found. The other three tri-
als that enrolled women with a multiple pregnancy reported out-
comes for each infant andwere incorporated as such into themeta-
analysis.
Cross-over trials
We excluded cross-over trials.
Cluster-randomised trials
We did not identify any cluster-randomised trials for inclusion in
this review, but we may include trials of this type in future up-
dates. If we do, we plan to include cluster-randomised trials in the
analyses along with individually-randomised trials. Their sample
sizes will be adjusted using the methods described in the Ccohrane
Handbook (Higgins 2011) using an estimate of the intracluster
6Prophylactic antibiotics for inhibiting preterm labour with intact membranes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
correlation co-efficient (ICC) derived from the trial (if possible), or
from another source. If ICCs from other sources are used, we will
report this and conduct sensitivity analyses to investigate the effect
of variation in the ICC. If we identify both cluster-randomised
trials and individually-randomised trials, we plan to synthesise the
relevant information. We consider it reasonable to combine the
results from both if there is little heterogeneity between the study
designs and the interaction between the effect of intervention and
the choice of randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Dealing with missing data
For included studies, we noted levels of attrition in the ’Risk of bias’
table. We planned to explore the impact of including studies with
high levels of missing data in the overall assessment of treatment
effect by using sensitivity analysis. For all outcomes, we carried
out analyses, as far as possible, on an intention-to-treat basis, i.e.
we attempted to include all participants randomised to each group
in the analyses, and all participants were analysed in the group
to which they were allocated, regardless of whether or not they
received the allocated intervention. The denominator for each
outcome in each trial was the number randomised minus any
participants whose outcomes were known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if the Tau²was greater than zero and either an I² was greater
than 30% or there was a low P value (less than 0.10) in the Chi²
test for heterogeneity.
Assessment of reporting biases
If 10 or more studies had contributed data to meta-analysis for any
particular outcome, we investigated reporting biases (such as pub-
lication bias) using funnel plots. We have assessed possible asym-
metry visually. If asymmetry was suggested by a visual assessment,
we planned to perform exploratory analyses to investigate it. In
this version of the review insufficient data were available to allow
us to carry out this planned analysis.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2012).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar. If clinical hetero-
geneity was evident sufficient to expect that the underlying treat-
ment effects differed between trials, or if substantial statistical het-
erogeneity was detected, we used random-effects meta-analysis to
produce an overall summary, if an average treatment effect across
trials was considered clinically meaningful.
The random-effects summary was treated as the average range of
possible treatment effects and we discussed the clinical implica-
tions of treatment effects differing between trials. If the average
treatment effect was not clinically meaningful, we did not com-
bine trials. Where random-effects analyses were used, the results
are presented as the average treatment effect with its 95% confi-
dence interval, and the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
If we identified substantial heterogeneity, we investigated it using
subgroup analyses. We considered whether an overall summary
was meaningful, and if so, used random-effects analysis to produce
it. We assessed subgroup differences by interaction tests available
within RevMan (RevMan 2012).
A priori subgroup analyses
The following subgroup analyses were planned.
• Macrolide antibiotics alone compared with no antibiotic.
• Beta-lactam antibiotics alone compared with no antibiotic.
• Macrolide and beta-lactam antibiotics compared with no
antibiotic.
• Antibiotics active against anaerobic bacteria compared with
no antibiotic.
• Antibiotics compared with no antibiotics commenced
between 28 to 36 completed weeks’ gestation versus less than 28
completed weeks.
Two additional subgroup analyses were included in this updated
of the review as follows.
• Any macrolide antibiotics (including macrolide antibiotics
used as a single agent or in combination with other types of
antibiotics) versus no macrolide antibiotics (including use of any
non-macrolide antibiotics or no antibiotics).
• Any beta-lactam antibiotics (including beta-lactam
antibiotics used as a single agent or in combination with other
types of antibiotics) versus no beta-lactam antibiotics (including
use of any non-beta-lactam antibiotics or no antibiotics).
For subgroup analyses the following subset of outcome measures
were included.
For the infant/child.
• Death or major long-term infant neurosensory impairment
at time of follow-up.
• Neurosensory impairment long-term: any, and moderate
and severe, cerebral palsy.
• Interval between randomisation and birth.
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• Birth prior to 37 weeks’ gestation.
• Perinatal mortality.
• Stillbirth.
• Neonatal death.
• Infant death.
• Birth within 48 hours of randomisation.
• Intraventricular haemorrhage.
• Necrotising enterocolitis.
For the woman.
• Serious adverse outcome related to antibiotic treatment
(respiratory arrest, cardiac arrest, death).
• Maternal adverse drug reaction.
• Maternal infection - chorioamnionitis/amnionitis.
Sensitivity analysis
We planned to carry out sensitivity analyses to explore the effect of
trial quality assessed by concealment of allocation, high attrition
rates (greater than 20%), or both, with poor-quality studies being
excluded from the analyses in order to assess whether this made
any difference to the overall result.
R E S U L T S
Description of studies
See Characteristics of included studies; and Characteristics of
excluded studies.
Results of the search
The previous review update included 11 trials: Cox 1996; Gordon
1995; Kenyon 2001a; McGregor 1991; Newton 1989; Newton
1991; Norman 1994; Oyarzun 1998; Romero 1993; Svare 1997;
Watts 1994. A further seven trials were identified and ex-
cluded for the reasons described in the table of excluded studies
(McCaul 1992; McGregor 1986; McGregor 1988; Morales 1988;
Nadisauskiene 1996; Saez-Llorens 1995; Winkler 1988).
In this update, 13 potentially eligible studies were reviewed
for inclusion. Three new studies were included: Keuchkerian
2005; Rajaei 2006; Reimer 1999) and 10 were excluded: Gurbuz
2004; Hensen 1987; Jones 2011; Lauterbach 2012.; Naef 1994;
Ogasawara 1996; Oszukowski 2000; Ovalle 2006; Ozden 2000;
Purwar 1997. In addition, one study Kenyon 2008a reported
longer outcomes of Kenyon 2001a.
The review now includes a total of 14 trials randomising 7837
women.
Included studies
Study population
All included studies used similar definitions of preterm labour,
which included the presence of uterine contractions and cervical
dilatation. As there is no accurate clinical test for the diagnosis of
preterm labour this diagnosis relies on a clinical decision which is
non-specific; the majority of women in the included studies went
on to deliver at term. All studies excluded women with symptoms
or signs suggestive of overt clinical infection of themother or fetus.
Gestational ages were similar in all trials with a mean gestational
age at entry of 30 to 32 weeks. Two trials Oyarzun 1998 and
Kenyon 2001a recruited participants between 34 and 36 weeks’
gestation. Reimer 1999 did not report on a specific gestational
age at recruitment. Multiple pregnancies were included in four of
the 14 trials (Cox 1996; Gordon 1995; Kenyon 2001a; Newton
1991). It was unclear whether Reimer 1999 included multiple
pregnancies.
Antibiotic regimens
The studies included a variety of antibiotics and a range of dos-
ing schedules. Antibiotics were administered intravenously in nine
of the trials. In three trials, they were administered orally only
(Kenyon 2001a; Oyarzun 1998; Rajaei 2006) and four trials used
a combination of intravenous infusion followed by oral media-
tion (Keuchkerian 2005; Newton 1989; Norman 1994; Romero
1993); the remainder using intravenous infusion alone. Ten tri-
als used a combination of antibiotics: Kenyon 2001a used a 2
x 2 factorial design to compare the effects of amoxicillin/clavu-
lanic acid and/or erythromycinwith placebo;Newton 1989 (ampi-
cillin and erythromycin), Newton 1991 (ampicillin and sulbac-
tam), Romero 1993 and Oyarzun 1998 (ampicillin/amoxycillin
and erythromycin), Norman 1994 and Svare 1997 (ampicillin and
metronidazole), Cox 1996 (ampicillin and sulbactamor clavulanic
acid), Watts 1994 (mezlocillin and erythromycin); Keuchkerian
2005 used amoxicillin and sulbactam. Four studies used single
agent therapy: McGregor 1991 (clindamycin); Gordon 1995 (cef-
tizoxime); Rajaei 2006 (erythromycin); and Reimer 1999 (me-
zlocillin). The duration of antibiotic treatment differed: eight
trials used a five- to seven-day course (Cox 1996; Keuchkerian
2005; McGregor 1991; Newton 1989; Newton 1991; Norman
1994; Oyarzun 1998; Svare 1997. Romero 1993 used an eight-
day course; and Kenyon 2001a, Watts 1994 and Rajaei 2006 10
days. Two studies used a shorter course of three days: Reimer 1999
and Gordon 1995 (initially commenced the trial using a five-day
course).
Other management strategies
In 13 of the 14 studies, the antibiotics were used with a policy for
tocolysis as standard management. In Kenyon 2001a, 56% of par-
ticipants received tocolysis. A variety of tocolytic agents were used
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in the trials including betamimetics, indomethacin, magnesium
sulphate and nifedipine. Antenatal corticosteroid administration
to stimulate fetal maturation was reported as part of the clinical
protocol in 12 of the included studies. The frequency of steroid us-
age varied between trials from approximately 30% (Gordon 1995;
Newton 1991) to greater than 90% (Keuchkerian 2005; Norman
1994; Oyarzun 1998; Rajaei 2006; Romero 1993; Svare 1997). In
Kenyon 2001a, over 80% of participants received antenatal corti-
costeroids.
Seven studies reported vaginal cultures for Group B Streptococcus
(GBS) as part of the study protocol. Four of these trials (McGregor
1991; Newton 1991; Oyarzun 1998; Romero 1993) reported
intrapartum antibiotic administration for women with a posi-
tive GBS culture, in addition to the study medication. Gordon
1995 withdrew women who had a positive GBS culture from
the study and administered intrapartum antibiotics. One study
Kenyon 2001a did not collect data on GBS status
Outcome measures
Outcome measures were not always clearly or consistently defined
or reported across the trials, with the exception of Kenyon 2001a
who reported precise definitions for all outcome measures. The
definition of neonatal sepsis was inconsistent across the included
studies and there were large differences in the rates of neonatal
infection reported. Svare 1997 reported a rate of neonatal sepsis of
22% in controls, whereas the overall rate for controls in all trials
was 8.5%. Kenyon 2001a reported on proven sepsis only (blood
culture positive), with a rate in the placebo arm of 2%. Kenyon
2001a reported the outcome of major cerebral abnormality (any
intraparenchymal cerebral bleed, hydrocephalus, any parenchymal
cysts (porencephalic or cystic leukomalacia) (personal communi-
cation) on ultrasound prior to hospital discharge. This outcome
has been included in the review. Additional neonatal outcomes
were included from Keuchkerian 2005 and Rajaei 2006 in this
update.
Long-term outcome data, up to seven years of age, were available
for one study (Kenyon 2001a) reported in Kenyon 2008a. The
follow-up included infants from the initial study who were born
to mothers enrolled in the UK, representing 50% of all infants
enrolled and 71% of all UK infants. The primary outcome was
defined as the presence of any level of functional impairment and
secondary outcomes included a range of medical and behavioural
outcomes. Educational attainment at seven years was assessed for
children attending school in England using results from National
Curriculum tests at Key Stage 1. The following outcomes from
this follow-up study have been included in the review: infant death
(deaths of liveborn infants to 12 months of age); functional im-
pairment (any i.e. severe,moderate or mild combined; andmoder-
ate and severe combined) and cerebral palsy (CP) measured using
proxy information provided by parents through a postal question-
naire (or by telephone in a small number) using validated tools.
Clinical assessment was not feasible due to the numbers of children
involved. Functional impairment was obtained using the Health
Utilities Index (HUI) Saigal 1994 fromwhich theMulti-Attribute
Health Status (MAHS) was derived. The proportion of missing
data (of those eligible for follow-up) for these included outcomes
are as follows: infant death (to 12 months of age (Nil); at seven
years of age, any functional impairment and moderate or severe
functional impairment and cerebral palsy (71%).The investigators
assessed the characteristics of the responders to the questionnaires
and found that they were “broadly similar to the total population
enrolled” in the ORACLE II trial (Kenyon 2001a).
Excluded studies
In total, 16 studies were excluded from this review (Gurbuz 2004;
Hensen 1987; Lauterbach 2012; McCaul 1992; McGregor 1986;
McGregor 1988; Morales 1988; Nadisauskiene 1996; Naef 1994;
Ogasawara 1996; Oszukowski 2000; Ovalle 2006; Ozden 2000;
Purwar 1997; Saez-Llorens 1995; Winkler 1988).
Five studies were excluded as women with rupture of the
membranes were randomised (Nadisauskiene 1996; Naef 1994;
Ogasawara 1996; Purwar 1997; Winkler 1988) and are covered
by another Cochrane review (Kenyon 2010). One study enrolled
women who were not in labour (McGregor 1988) and in another,
the intervention was not an antibiotic (Lauterbach 2012). Three
studies were excluded as they used a quasi-randomised method
of treatment allocation (Ovalle 2006; Ozden 2000; Saez-Llorens
1995) and six studies were excluded as additional information to
enable assessment of quality and eligibility were not able to be
obtained from the authors (Gurbuz 2004; Hensen 1987; McCaul
1992; McGregor 1986; Morales 1988; Oszukowski 2000). A fur-
ther study (Jones 2011), reported a methodological study using
data from the ORACLE follow-up study (Kenyon 2008a).
Refer to tableCharacteristics of excluded studies for further details.
Risk of bias in included studies
Overall the quality of the included trials was good. Refer to
Characteristics of included studies for further details. for further
details and to Figure 1 ; Figure 2 , for a summary of ’Risk of bias’
assessments.
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Figure 1. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
In seven trials, the method of sequence generation was unclear
(Newton 1989; Newton 1991; Norman 1994; Oyarzun 1998;
Rajaei 2006; Reimer 1999; Watts 1994). The remaining seven
trials were assessed as having a low risk of bias with respect to
sequence generation (Cox 1996; Gordon 1995; Kenyon 2001a;
Keuchkerian 2005; McGregor 1991; Romero 1993; Svare 1997).
Allocation concealment
In five trials, the method of allocation concealment was unclear
(Keuchkerian 2005; Oyarzun 1998; Rajaei 2006; Reimer 1999;
Watts 1994). The nine remaining trials were assessed as having a
low risk of bias with respect to allocation concealment.
Blinding
Twelve of the 14 included trials were placebo-controlled, with
blinding of caregivers and participants (Cox 1996; Gordon 1995;
Kenyon 2001a; Keuchkerian 2005; McGregor 1991; Newton
1989; Newton 1991; Oyarzun 1998; Rajaei 2006; Romero 1993;
Svare 1997; Watts 1994. Blinding of outcome assessment was
assessed as low risk of bias in these 12 trials.
Two trials were assessed as high risk of bias for both blinding of
caregivers and participants and outcome assessment as a placebo
was not used (Norman 1994 and Reimer 1999).
Incomplete outcome data
Thirteen studies were assessed as being at low risk of bias for
attrition bias with three studies reporting no losses to follow-up
(Gordon 1995; Keuchkerian 2005; Watts 1994) and 10 studies
reporting less than 20% loss to follow-up (Cox 1996; Kenyon
2001a; McGregor 1991; Newton 1989; Newton 1991; Norman
1994; Oyarzun 1998; Rajaei 2006; Romero 1993; Svare 1997).
In one trial (Reimer 1999), it was unclear whether attrition bias
was present. Long-term follow-up of infants (to seven years of
age) was included for one trial (Kenyon 2001a). This trial was
assessed as having a low risk of bias for these outcomes as 71% of
all eligible infants were included in the analysis and comparison
with outcomes in the general population showed similar event
rates (cerebral palsy).
Selective reporting
Twelve studies were assessed as being at low risk of bias for selective
reporting (Cox 1996; Gordon 1995; Kenyon 2001a; Keuchkerian
2005; McGregor 1991; Newton 1989; Newton 1991; Norman
1994; Oyarzun 1998; Romero 1993; Svare 1997; Watts 1994) as
all expected outcomes were reported.
In two studies, the risk of bias was unclear (Rajaei 2006; Reimer
1999). Reimer 1999 did not report neonatal outcomes however
all prespecified outcome measures were reported.
Other potential sources of bias
Thirteen studies were assessed as being at low risk of bias for other
potential sources of bias based on baseline characteristics being
similar between groups and no other bias apparent (Cox 1996;
Gordon 1995; Kenyon 2001a; Keuchkerian 2005; McGregor
1991; Newton 1989; Newton 1991; Oyarzun 1998; Rajaei 2006;
Reimer 1999; Romero 1993; Svare 1997; Watts 1994). One trial
(Norman 1994) (which showed positive pregnancy prolongation
outcomes) was stopped early following an interim analysis and was
assessed as being unclear risk of bias.
Effects of interventions
The meta-analysis includes outcomes from 14 included trials ran-
domising 7837 women.
Comparison 1: Any antibiotics versus no antibiotics
Primary outcome measures
For the infant/child
Perinatal and infant mortality
No statistically significant difference was demonstrated in perina-
tal mortality (risk ratio (RR) 1.22, 95% confidence interval (CI)
0.88 to 1.69; 10 studies with 7304 women) Analysis 1.1 or still-
birth (RR 0.73, 95% CI 0.43 to 1.26; eight studies, 7080 infants)
Analysis 1.2. However, an increase in neonatal deaths was shown
for infants of women receiving any prophylactic antibiotics when
compared with placebo (RR 1.57, 95% CI 1.03 to 2.40; number
needed to treat to harm (NNTH) 149, 95% CI 2500 to 61; nine
studies; 7248 infants) Analysis 1.3.
A funnel plot for the analysis of perinatal mortality (Figure 3),
including the 10 studies, was reasonably symmetrical therefore not
suggestive of important reporting bias or small-study effect.
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Figure 3. Funnel plot of comparison: 1 Any antibiotics versus no antibiotics, outcome: 1.1 Perinatal
mortality.
Long-term outcomes
Long-term outcomes for the infant/child were available from UK
infants enrolled in the large ORACLE II trial Kenyon 2001a.
When compared to no antibiotics (placebo), no difference was
shown in infant deaths (RR 1.06, 95% CI 0.68 to 1.67; 4654
infants) Analysis 1.4, any functional impairment (RR 1.10, 95%
CI 0.99 to 1.23) Analysis 1.5, or moderate to severe impairment
(RR1.07, 95%CI 0.89 to 1.28; 3052 infants) Analysis 1.6 at seven
years of age.
A marginally non-statistically significant increase in cerebral palsy
(CP) at seven years of age was shown (RR 1.82, 95% CI 0.99 to
3.34; 3173 infants) Analysis 1.7.
For the woman
No data were available for other prespecified primary outcomes
for the woman, of serious adverse outcome related to antibiotic
treatment (respiratory arrest, cardiac arrest, death) or adverse drug
reaction requiring cessation of treatment.
Secondary outcome measures
For the infant
Pregnancy prolongation
No difference was shown in birth prior to 36 or 37 weeks’ gesta-
tion (RR 0.98, 95% CI 0.92 to 1.05; 10 studies, 7387 women)
Analysis 1.12. None of the included trials reported the prespeci-
fied outcomes of birth prior to 28 or 34 weeks’ gestation.
A funnel plot for the analysis of preterm birth (less than 36 or
less than 37 weeks) (Figure 4 ) was symmetrical and therefore not
suggestive of important bias or small-study effect.
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Figure 4. Funnel plot of comparison: 1 Any antibiotics versus no antibiotics, outcome: 1.12 Preterm birth (<
36 or < 37 weeks).
The Interval between randomisation and birth (days) was longer
for women receiving antibiotics (average mean difference (MD)
5.59 days, 95% CI 0.31 to 10.87; random-effects, Tau² = 25.22,
I² = 64%) Analysis 1.11. However, no significant difference was
shown in the outcome of birth within 48 hours (RR 1.04, 95%
CI 0.89 to 1.23), or seven days from randomisation (RR 0.98,
95% CI 0.87 to 1.10) Analysis 1.10, or for gestational age at birth
(average MD 0.53 days, 95% CI 0.00 to 1.06; random-effects,
Tau² = 0.27, I² = 40%) Analysis 1.13.
Upon exploration of the possible reasons for the heterogeneity for
the outcomes of Interval from randomisation to birth and gesta-
tional age at birth, by examining clinical features of the trials (in-
cluding population characteristics such as gestation at enrolment,
diagnosis of preterm labour and other aspects of routine manage-
ment of preterm labour, and antibiotic administration regimens),
we considered an overall summary was clinically meaningful using
a random-effects analysis.
Other neonatal outcomes
No significant difference was shown in the following neonatal
outcomes.
• Birthweight (average MD 58.38, 95% CI -26.24 to 143.00;
random-effects, Tau² = 8895.21, I² = 49%; 12 trials, 7531
infants) Analysis 1.14.
• Birthweight less than 2500 g (average RR 0.97, 95% CI
0.81 to 1.15; random-effects, Tau² = 0.02, I² = 45%; five trials,
6682 infants) Analysis 1.15.
• Admission to neonatal intensive care or special care (average
RR 0.82, 95% CI 0.62 to 1.10, random-effects Tau² =0.06, I² =
69%; five trials, 6875 infants) Analysis 1.16.
After close inspection of the characteristics of the studies in the
analyses (as defined above) for the above outcomes (birthweight
less than 2500 g; birthweight; and admission to neonatal Intensive
care), we decided that average treatment effect across trials was
clinicallymeaningful and therefore proceededwith random-effects
meta analysis (where required) to combine these outcome data.
• Mechanical ventilation (RR 1.02, 95% CI 0.84 to 1.24;
one trial, 6241 infants) Analysis 1.17.
• Respiratory distress syndrome (RR 0.99, 95% CI 0.84 to
1.16; nine trials, 7200 infants) Analysis 1.18.
• Neonatal positive blood culture (RR 1.01, 95% CI 0.69 to
1.49; three trials, 6526 infants) Analysis 1.19.
• Neonatal sepsis (RR 0.86, 95% CI 0.64 to 1.16; 10 trials,
7386 infants) Analysis 1.20.
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A funnel plot for the analysis of neonatal sepsis was reasonably
symmetrical and therefore not suggestive of the presence of im-
portant reporting bias or small-study effect. Figure 5.
Figure 5. Funnel plot of comparison: 1 Any antibiotics versus no antibiotics, outcome: 1.20 Neonatal sepsis.
• Intraventricular haemorrhage (RR 0.76, 95% CI 0.48 to
1.19; five trials, 6813 infants) Analysis 1.21.
• Necrotising enterocolitis (RR 1.06, 95% CI 0.64 to 1.73;
six trials, 6880 infants) Analysis 1.22.
• Major cerebral abnormality (RR 1.00, 95% CI 0.66 to
1.51; one trial, 6241 infants) Analysis 1.23.
• Chronic lung disease (RR 1.17, 95% CI 0.78 to 1.76; one
trial, 6241 infants) Analysis 1.24.
Data were not available for the following prespecified secondary
outcomes: cerebral cystic lesions (periventricular leukomalacia,
porencephalic cysts) (although Kenyon 2001a reported any major
cerebral abnormality on ultrasound prior to discharge, which was
included); intraventricular haemorrhage (grades three and four);
Apgar score of less than seven at five minutes; retinopathy of pre-
maturity (all stages); retinopathy of prematurity (stages III and
IV).
A funnel plot for the analysis of preterm birth (less than 36 or
less than 37 weeks) (Figure 4 was symmetrical and therefore not
suggestive of the presence of important bias or small-study effect.
For the woman
Meta-analysis of 10 studies including 7371 women showed a sta-
tistically significant reduction in maternal infection (chorioam-
nionitis/endometritis) for women receiving antibiotics (RR 0.74,
95% CI 0.63 to 0.86) giving a number needed to treat to benefit
(NNTB) of 34, 95% CI 24 to 63) Analysis 1.9. A funnel plot for
this analysis ( Figure 6 ), including the 10 studies was asymmet-
rical. This suggests that there may be some important biases or
small-study effects in the set of studies in this analysis and so these
results should be viewed with caution.
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Figure 6. Funnel plot of comparison: 1 Any antibiotics versus no antibiotics, outcome: 1.9 Maternal
infection.
Maternal adverse drug reaction requiring cessation of treatment
was increased in the group of women receiving antibiotics but this
did not reach statistical significance (RR 1.32, 95%CI 0.92, 1.89;
five studies, 626 women) Analysis 1.8.
Health service utilisation
None of the included studies reported on the prespecified outcome
of length of hospital stay for women or infants.
Subgroup analyses
Subgroup analyses were undertaken as follows: Antibiotic versus no
antibiotics subgrouped by type of antibiotic; and Any macrolide versus
no macrolide antibiotics; and Any beta-lactam versus no beta-lactam
antibiotics.Due to insufficient data, the planned subgroup analysis
relating to different gestational age groups at commencement of
antibiotics was not able to be undertaken.
Comparison 2: Antibiotic versus no antibiotics
subgrouped by type of antibiotic
Exploration of differential effects of single and combination an-
tibiotic therapy compared with no antibiotics was undertaken us-
ing the following subgroups.
• Treatment with macrolide antibiotics alone compared with
no antibiotic.
• Treatment with beta-lactam antibiotics alone compared
with no antibiotic.
• Treatment with macrolide and beta-lactam antibiotics
compared with no antibiotic.
• Treatment with antibiotics active against anaerobic bacteria
compared with no antibiotic.
Primary outcome measures
For the infant/child
No differences were shown for perinatal mortality, stillbirth,
neonatal or infant death.
An increase in CP for the subgroup of children exposed to
macrolide (erythromycin) and beta-lactam antibiotics combined
compared with no antibiotics was shown (RR 2.83, 95% CI 1.02
to 7.88), giving the NNTH of 35 (95% CI 333 to 9). Cerebral
palsy was not statistically significantly increased for beta-lactam
alone (RR 1.22, 95% CI 0.41 to 3.63), or for macrolide alone
(RR 1.42, 95% CI 0.48 to 4.15). The results were not statistically
significantly across subgroups (Chi² = 1.41, df = 2 (P = 0.49), I²
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= 0%), Analysis 2.7.
Nodifferencewas shown in themeasures of functional impairment
at seven years of age (test for subgroup differences: Chi² = 0.46,
df = 2 (P = 0.80), I² = 0%). A small trend toward an increase in
any functional impairment was shown in the subgroups of infants
exposed to macrolide and macrolide and beta-lactam antibiotics
(RR 1.13, 95% CI 0.94 to 1.35) Analysis 2.5.
For the woman
No data were available for other prespecified primary outcomes
for the woman, of serious adverse outcome related to antibiotic
treatment (respiratory arrest, cardiac arrest, death) or adverse drug
reaction requiring cessation of treatment.
Secondary outcome measures
For the infant/child
Pregnancy prolongation
In the subgroup analysis of antibiotics active against anaerobes,
including three studies (McGregor 1991; Norman 1994; Svare
1997) with 293 women, a statistically significant increase in the
Interval between randomisation and birth (three studies with 293
women) (MD 10.50 days, 95% CI 4.95 to 16.06) was shown,
which was not present in the other subgroups, (test for subgroup
differences: Chi² = 13.41, df = 3 (P = 0.004), I² = 77.6%) Analysis
2.11.
No statistically significant differences were evident in short-term
infant outcomes across these subgroups
For the woman
No statistically significant differences were evident across the sub-
groups for the two outcomes for women included in this review
of maternal infection or adverse drug reaction requiring cessation
of treatment.
Comparison 3: Any macrolide versus no macrolide
antibiotics
Primary outcome measures
For the infant/child
The use of anymacrolide (erythromycin and erythromycin and co-
amoxiclav combined) comparedwith nomacrolide antibiotics (co-
amoxiclav or placebo) was associated with an increase in neonatal
death (RR 1.52, 95%CI 1.05 to 2.19, NNTH139, 95%CI 1429
to 61; three trials, 6684 infants) Analysis 3.3.
Data from the UK children in the ORACLE II study showed an
increase in any functional impairment (RR 1.11, 95% CI 1.01 to
1.20, NNTH 24, 95% CI 263 to 13) Analysis 3.5 at seven years
of age (3052 children) and CP (RR 1.90, 95% CI 1.20 to 3.01,
NNTH 64, 95% CI 286 to 29; 3173 children) Analysis 3.7. No
difference was shown in moderate/severe functional impairment
at seven years of age (RR 1.08, 95% CI 0.93, 1.26; 3052 children)
Analysis 3.6.
No difference was shown in:
• Perinatal mortality (RR 1.20, 95% CI 0.89 to 1.60;four
trials, 6740 infants) Analysis 3.1.
• Stillbirth (RR 0.70, 95% CI 0.41 to 1.20; two trials, 6518
infants) Analysis 3.2.
• Infant death (RR 1.47, 95% CI 0.99 to 2.18; one trial,
4583 infants) Analysis 3.4.
For the woman
No data were available for other prespecified primary outcomes
for the woman, of serious adverse outcome related to antibiotic
treatment (respiratory arrest, cardiac arrest, death) or adverse drug
reaction requiring cessation of treatment.
Secondary outcome measures
For the infant/child
Pregnancy prolongation
No difference was shown in any other outcomes included in this
analysis as follows.
• Birth within 48 hours of randomisation (RR 1.08, 95% CI
0.94 to 1.25; three trials, 6691 infants) Analysis 3.10.
• Interval between randomisation and birth (MD 1.07, 95%
CI -3.58, 5.72; random-effects: Tau² = 8.45; I² = 33%; three
trials, 6386 infants) Analysis 3.11 Heterogeneity: Tau² = 8.45;
Chi² = 3.60, df = 2 (P = 0.17); I² = 44%.
• Birth prior to 36 or 37 weeks’ gestation (RR 1.01, 95% CI
0.95 to 1.07; four trials, 6784 infants) Analysis 3.12.
Other neonatal outcomes
No difference was shown in any other outcomes included in this
analysis as follows.
• Respiratory distress syndrome (RR 1.04, 95% CI 0.90 to
1.21; four trials, 6740 infants) Analysis 3.13.
• Intraventricular haemorrhage (RR 0.96, 95% CI 0.62 to
1.49; two trials, 6516 infants) .Analysis 3.14.
• Necrotising enterocolitis (RR 1.16, 95% CI 0.74 to 1.80;
two trials, 6516 infants) Analysis 3.15.
For the woman
Adverse drug reaction requiring cessation of treatment was in-
creased for women receiving any macrolide antibiotics (ery-
thromycin), however this finding was not statistically significant
(RR 1.49, 95% CI 0.93 to 2.40; two trials, 331 women) Analysis
3.8 .
No difference was shown for the outcome of maternal infection
(average RR 0.66, 95% CI 0.41 to 1.07; random-effects: Tau² =
0.18, I² = 57%; four trials, 6745 women) Analysis 3.9.
Comparison 4: Any beta-lactam versus no beta-
lactam
Primary outcome measures
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For the infant/child
The use of any beta-lactam antibiotics (including beta-lactam an-
tibiotics alone or in combination with erythromycin) versus no
beta-lactam antibiotics (including erythromycin alone or no an-
tibiotics) was associated with an increase in neonatal death (RR
1.51, 95% CI 1.06 to 2.15, NNTH 143, 95% CI 1250 to 63;
seven trials, 7053 infants) Analysis 4.3. Data fromUK children in
the ORACLE II study showed an increase in CP (RR 1.67, 95%
CI 1.06 to 2.61, NNTH 79, 95% CI 909 to 33; one trial, 3173
children) Analysis 4.7.
No difference was shown for the following outcomes.
• Perinatal mortality (RR 1.12, 95% CI 0.84 to 1.48; eight
trials, 7109 infants) Analysis 4.1,
• Stillbirth (RR 1.10, 95% CI 0.76 to 1.58; six trials, 6887
infants) Analysis 4.2,
• Infant death (RR 0.94, 95% CI 1.64 to 1.38; one trial,
4654 infants) Analysis 4.4.
• Any functional impairment (RR 1.02, 95% CI 0.93 to
1.11) Analysis 4.5 or moderate/severe functional impairment
(RR 1.03, 95% CI 0.88 to 1.20) at seven years of age, (one trial,
3052 children) Analysis 4.6
For the woman
No data were available for other prespecified primary outcomes
for the woman, of serious adverse outcome related to antibiotic
treatment (respiratory arrest, cardiac arrest, death) or adverse drug
reaction requiring cessation of treatment.
Secondary outcome measures
For the infant/child
Pregnancy prolongation
No difference was shown in any other outcomes included in this
analysis as follows.
• Birth within 48 hours of randomisation (RR 1.02, 95% CI
0.89 to 1.18; four trials, 6800 infants) Analysis 4.10.
• Interval between randomisation and birth (average MD
3.92, 95% CI -5.08, 12.92; random-effects: Tau² = 44.55; I² =
72%; three trials, 6386 infants) Analysis 4.11.
• Birth prior to 36 or 37 weeks’ gestation (RR 0.98, 95% CI
0.92 to 1.04; eight trials, 7185 infants) Analysis 4.12.
Other neonatal outcomes
No difference was shown in any other outcomes included in this
analysis as follows.
• Respiratory distress syndrome (RR 1.02, 95% CI 0.88 to
1.19; eight trials, 7108 infants) Analysis 4.13.
• Intraventricular haemorrhage (RR 0.86, 95% CI 0.56 to
1.31; four trials, 6721 infants) Analysis 4.14.
• Necrotising enterocolitis (RR 0.72, 95% CI 0.27 to 1.92;
five trials, 6788 infants) Analysis 4.15.
For the woman
Maternal adverse drug reaction requiring cessation of treatment
was increased for women receiving any beta-lactam antibiotics
compared to no beta-lactam antibiotics (RR 1.61, 95% CI 1.02
to 2.54; NNTH 17, 95% CI 526 to 7; four trials, 523 women)
Analysis 4.8. A reduction was shown in maternal infection (RR
0.80, 95% CI 0.69 to 0.92; NNTB 47, 95% CI 31 to 119; eight
trials, 7182 women) Analysis 4.9.
D I S C U S S I O N
The trials in this review overall were of reasonably sound method-
ology, the populations studied were homogeneous, and the results
were generally consistent across the trials. The pooled analyses of
the 14 trials included in this review were dominated by the re-
sults of the ORACLE II trial Kenyon 2001a. This trial differed
from the majority of the trials in that (i) it was one of only three
trials in which the antibiotics were used orally rather than intra-
venously, and (ii) it was one of only two trials which recruited
women after 34 weeks’ gestation. For these two reasons, it is pos-
sible therefore that Kenyon 2001a participants may have been less
likely to demonstrate a beneficial effect from antibiotics (such as
meaningful prolongation of pregnancy), but for almost all short-
term outcomes, the results of Kenyon 2001a are consistent with
those of the other trials combined.
While the interval between randomisation and birth was longer
for women allocated to any prophylactic antibiotics versus no an-
tibiotics, no benefit was shown in other measures of pregnancy
prolongation or clinically important short-term outcomes for the
infant. Consistent with these findings, no benefit was shown in
subgroup analyses by type of antibiotic versus placebo or any ery-
thromycin versus no erythromycin or any beta-lactam antibiotics
versus no beta-lactams. The review identified some evidence of
harm in short- and long-term infant/child outcomes associated
with antibiotic exposure.
An increase in neonatal deaths was shown comparing any antibi-
otic with placebo and also when comparing any macrolide to no
macrolide (erythromycin) and any co-amoxiclavwith no co-amox-
iclav. The number need to treat to harm (NNTH) statistic indi-
cates that on average 149, 139, and 143 infants respectively ex-
posed to antibiotics would result in one additional neonatal death
(although confidence intervals (CIs) were wide, ranging from 61
to 2500 across these comparisons). Follow-up data at seven years
of age from the UK children whose mothers joined the ORACLE
II trial (Kenyon 2001a) showed the prescription of any macrolide
antibiotic (erythromycin) was associated with an increase in func-
tional impairment; the NNTH statistic showed that (on average)
34 infants (95% CI 24 to 63) being exposed to antibiotics would
result in one additional child with functional impairment. The
risk of cerebral palsy (CP) was also increased by exposure to either
any erythromycin versus none, or any co-amoxiclav (beta-lactum)
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versus none, and also when used in combination versus placebo,
although the overall risk was low. The average number exposed
to antibiotics to cause one additional case of CP was 64, 79 and
35 respectively with wide 95% CIs ranging from 9 to 909 across
these comparisons.
The subgroup analysis of antibiotics active against anaerobic bacte-
ria including three studies [McGregor 1991 (using clindamycin);
Norman 1994 and Svare 1997 (both using a combination of ampi-
cillin and metronidazole)], showed a statistically significant in-
crease in the number of days from enrolment into the trial to
birth of 11 days on average (95% CI 5 to 16). Anaerobic bacteria
and the anaerobes of bacterial vaginosis (especially the Bacteroides
species) have been associated with preterm labour, and it may be
that antibiotics with anti-anaerobic activity are more effective in
delaying birth. It should be noted, however, that this delay was not
shown to confer benefit in terms of clinically important neonatal
or longer-term outcomes.
The long-term outcome data in this review came from the well-
conducted ORACLE II trial (The ORACLE Children Study -
OCS) Kenyon 2008b. The results were derived from infants born
to mothers enrolled in the UK representing 71% of the total UK
study population. The authors have presented detailed analyses
in support of the generalisability of the findings to the UK pop-
ulation Marlow 2012. The rate of CP among the placebo group
was low (1.6%) as many of the babies went on to be born at
term. However, comparing the rate of CP among the study group
with that reported from a Child CP register in the UK, the preva-
lence of CP was shown to be higher among children in the OR-
ACLE Children Study Marlow 2012. The investigators reported
a standardised morbidity ratio in the OCS children (spontaneous
preterm labour with intact membranes) of 3.12 (95% CI 2.47-
3.87) Marlow 2012. While not included in this review, no dif-
ferences were reported in the OCS on educational attainment at
seven years across the ORACLE II study groups.
The outcome of CP and functional impairment was largely deter-
mined by parental questionnaire and, while not as robust as clinical
assessment, the primary outcome, and some of the secondary out-
comes, were obtained using a validated tools Saigal 1994 . While
chance cannot be ruled out completely, it would not be wise to
dismiss this finding of increase CP out of hand.
The causal pathway for these findings is unclear. The pathways
leading to human parturition are many and incompletely under-
stood. Subclinical infection and inflammation are likely to play a
role in a proportion of spontaneous preterm births, but the pro-
portions may be lower than anticipated (evidence suggests sub-
clinical infection rates of 13% to 22% in women with intact mem-
branes Romero 2006). It could be that, if an episode of preterm
labour is infective in origin, maternal defences facilitated by the
antibiotics may work to suppress labour but not the associated in-
trauterine and fetal inflammation. This continuing environment
could lead to fetal brain injury. A significant proportion of women
(and/or their babies) presenting in spontaneous preterm labour
may not have underlying infection and therefore will not benefit
from treatment with antibiotics and may even be harmed.
The lack of benefit from the antibiotics may be as a consequence of
insufficient transplacental transfer of commonly used antibiotics
(Heikkinen 2000) and consideration of novel routes of adminis-
tration may be required (Keelan 2011). Unfortunately, the diag-
nosis of subclinical infection remains elusive although advances
are being made (Cobo 2009; Kayem 2009; Romero 2010). The
subgroup of women with possible subclinical infection were not
identified within the trials in this review.
Despite prolongation of pregnancy and reductions in maternal in-
fection, the absence of benefit for any clinically important short-
term neonatal outcomes and findings of an increase in neonatal
death, functional impairment and CP in children at seven years
old supports not giving antibiotics to women in preterm labour
with intact membranes in the absence of signs of infection. Fur-
ther research is required to develop sensitive markers of subclinical
infection for women in preterm labour with intact membranes,
as this is a group that might benefit from future novel interven-
tions including new modalities of antibiotic therapy. Results from
this review stress the importance of future trials of interventions
to prevent preterm birth must include assessment of important
longer-term child outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The findings of this review do not support the routine use of
prophylactic antibiotics for women in preterm labour with intact
membranes without signs of infection.
Implications for research
Further research is required to develop sensitive markers of sub-
clinical infection for women in preterm labour with intact mem-
branes, as this is a group that might benefit from future novel
interventions including new modalities of antibiotic therapy. Re-
sults from this review stress the importance of future trials of in-
terventions to prevent preterm birth must include assessment of
important longer-term child outcomes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cox 1996
Methods Single-centre prospective placebo-controlled randomised clinical trial. Dallas, Texas US
Participants 86 women 24-34 weeks’ gestation (mean 30 weeks), in preterm labour (cervical change
with contractions). Multiple births were included.
Exclusions: ruptured membranes, fetal or maternal complications necessitating delivery
Multiple births were included.
Interventions IV ampicillin 2 g with sulbactam 1 g every 6 h x 8 doses, followed by ampicillin -
clavulanate 250 mg every 8 h x 5 days or placebo
Outcomes Primary outcome: delivery > 36 weeks. Other outcomes - maternal: preterm delivery,
days of prolongation (in time categories, not mean days), adverse drug reaction.
Neonatal: BW, neonatal morbidity and mortality.
Notes Pre-trial sample size estimation, 39 required in each arm. 86 were randomised, 8 post-
randomisation exclusions. Neither tocolysis nor maternal corticosteroid steroids were
used.
Additional information on trial methods was received from author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers ta-
ble.
Allocation concealment (selection bias) Low risk “Consecutive, numbered, sealed
envelopes”. Did not state whether opaque
however, assignment was by pharmacist
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled using identical admin-
istration regimen in the 2 study groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not clear, but probably low risk. Placebo-
controlled trial.
Selective reporting (reporting bias) Low risk All expected outcome results reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk < 10% drop-out rate (total of 6 women)
- due to delivery before study commenced
or delivered elsewhere.No further informa-
tion
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Cox 1996 (Continued)
Incomplete outcome data longer term out-
comes (attrition bias)
All outcomes
Unclear risk Not applicable.
Other bias Low risk None apparent.
Gordon 1995
Methods Single-centre prospective placebo-controlled randomised clinical trial. Ohio State Uni-
versity Centre, US
Participants 117 women 24-35 weeks’ gestation in preterm labour receiving tocolysis.
Exclusions: ruptured membranes, higher order multiple pregnancies, advanced cervical
dilatation, suspected fetal compromise, recent use of antibiotics, recent positive GBS
vaginal culture, evidence of maternal infection
Interventions IV ceftizoxime 2 g every 8 h for 5 days (initially), later reduced to 3 days because of
patients’ refusal
Outcomes Primary outcome: delivery > 35 weeks. Other outcomes -
Maternal: infection, interval to delivery (mean days), preterm delivery.
Neonatal: GA, BW, sepsis or infection.
Notes Pre-trial sample size estimation indicated that 64 participants were required in each arm
Findings are compared with other study findings in commentary. Toclolytics given to all
women
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
schedule. Stratification by twin pregnancy
Allocation concealment (selection bias) Low risk By the pharmacy.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “double-blind placebo controlled trial” us-
ing identical administration regimen in the
two study groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not clear, but probably low risk. Placebo-
controlled trial.
Selective reporting (reporting bias) Low risk All expected outcome results reported
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Gordon 1995 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up.
Incomplete outcome data longer term out-
comes (attrition bias)
All outcomes
Unclear risk Not applicable.
Other bias Low risk None apparent.
Kenyon 2001a
Methods Multicentre placebo-controlled randomised clinical trial across 161 centres (2 x 2 factorial
design)
Participants 6295 women at less than 37 weeks’ gestation. (GA at entry was approximately 31 weeks)
.
with intact membranes and thought to be in preterm labour and clinical uncertainty as
to whether to use antibiotics.
Exclusions: women already receiving antibiotics, or when there was a perceived require-
ment for antibiotics; when immediate delivery was desirable or imminent; fetus not
premature enough to cause concern; contraindications such as allergy, jaundice, use of
theophylline, cabamazepine, digoxin, disopyramide, ternefadine, or astemizole (all of
which are contra-indicated with erythromycin)
Interventions 4 study groups as follows (all oral administration): n = 6241.
1. 325 mg co-amoxiclav plus 250 mg erythromycin; n = 1551.
2. 325 mg co-amoxiclav plus erythromycin placebo; n = 1534.
3. 250 mg erythromycin plus co-amoxiclav placebo; n = 1600.
4. co-amoxiclav placebo plus erythromycin placebo. n = 1556.
All study medication was given orally every 6 h for 10 days or until delivery, whichever
occurred earlier
Outcomes Primary outcome: Composite neonatal outcome of neonatal death or major adverse
outcome - i.e. chronic lung disease or major cerebral abnormality on ultrasound before
hospital discharge.
Secondary outcomes: delivery within 48 h and within 7 days, mode of delivery, number
of days in hospital, maternal antibiotic prescription after delivery and before discharge,
GA at delivery, BW < 2500 g or < 1500 g, admission to NICU or special care baby unit,
neonatal mechanical ventilation, RDS, treatment with surfactant, neonatal sepsis, NEC
Long-term follow-up on a subset of enrolled infants at 7 years of age as follows: Functional
impairment was assessed using the Mark III Multi-Attribute Health Status classification
system. Primary outcome was defined as any level of functional impairment (severe,
moderate or mild). Other outcomes included death, behaviour (using the Strengths
and Difficulties questionnaire) prespecified questions on respiratory symptoms, hospital
admissions, convulsions, other prespecified medical conditions and demographic data.
Educational attainment was evaluated for the subset of children in England using data
from National Cirriculum Tests at 7 years of age (Key Stage 1)
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Kenyon 2001a (Continued)
Notes Pre-trial sample size estimation based on primary outcome measure.
Additional data received and included on perinatal mortality, cerebral abnormalities,
pregnancy prolongation. Tocolytics given in just over half of women enrolled and ma-
ternal corticosteroids in the majority
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomly generated
blocks of 4.
Allocation concealment (selection bias) Low risk Sequentially numbered boxes of identical
appearance dispensed centrally
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled trial using identical ad-
ministration regimen in the 2 study groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not clear, but probably low risk. Placebo-
controlled trial.
Selective reporting (reporting bias) Low risk All expected outcome results reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 40 women (<1%) were lost to follow-up -
fairly consistent across the groups
Incomplete outcome data longer term out-
comes (attrition bias)
All outcomes
Low risk Long-term follow-up at 7 years of age was
undertaken for the infants of women en-
rolled in the UK only; 71% of all children
eligible for follow-up (representing 50% of
the total trial population) were included in
this assessment
Other bias Low risk None apparent.
Keuchkerian 2005
Methods Single-centre placebo-controlled randomised clinical trial. Montevideo, Uruguay
Participants 96 women 24 to 34 weeks’ gestation, singleton pregnancy, intact amniotic membranes,
no cerclage, diagnosis of threatened preterm labour, cervical dilatation of < 4 cm
Exclusions: haemorrhage, congenital anomalies, polyhydramnios, clinical urinary infec-
tion, fetal growth retardation, maternal pathologies such as diabetes/hypertension/pre-
eclampsia, allergies to amoxicillin
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Keuchkerian 2005 (Continued)
Interventions Amoxicillin 1000 mg sulbactam 500 mg IV every 8 h during first 48 h, then amoxicillin
250 mg sulbactam 250 mg every 8 h for 5 days
Control: placebo IV fluid, then tablets that look exactly the same as intervention
Outcomes Primary outcomes: delivery prior to 37 weeks, delivery prior to 32 weeks, delivery within
7 days
Other outcomes: neonatal/fetal - Apgar score < 7 at 1 min, RDS, Intraventricular haem-
orrhage all grades, fetal deaths, neonatal deaths, neonatal sepsis, gestation at birth, BW
Notes Prior sample size estimation indicated that 40 participants were required in each arm
Tocolysis and maternal corticosteroids were included as part of the study protocol
Multiple pregnancy excluded. Laboratory sponsored.
All data analysed before knowing if belonged to treatment or control group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “a simple randomisation was generated by
computer” . “ The Laboratory that man-
ufactured the manufactured amoxicillin-
sulbactam, randomised both the antibiotic
and the placebo”
Allocation concealment (selection bias) Unclear risk Sealed envelopes were used. Consecutive or
opaque not mentioned however they were
prepared by the laboratory
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled trial using identical ad-
ministration regimens in the 2 study
groups. “All study personnel and partic-
ipants were blinded to treatment assign-
ment for the duration of the study.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not clear, but probably low risk. Placebo-
controlled trial.
Selective reporting (reporting bias) Low risk All expected outcome results reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up.
Incomplete outcome data longer term out-
comes (attrition bias)
All outcomes
Unclear risk Not applicable.
Other bias Low risk None apparent.
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McGregor 1991
Methods Single-centre placebo-controlled randomised clinical trial. Denver, Colorado, Canada
Participants 117 women < 35 weeks’ gestation (mean 30.5 weeks) in preterm labour receiving tocol-
ysis. Exclusions: ruptured membranes, multiple pregnancy, suspected fetal compromise,
maternal infection and other maternal medical conditions
Interventions IV clindamycin 900 mg every 8 h x 9 doses or identical placebo. IV therapy was followed
by oral clindamycin 300 mg every 6 h x 4 days or identical placebo
Outcomes Primary outcome: delivery > 36 weeks. Other outcomes -
Maternal:meandays of prolongation, infection, pre labour PROM, adverse drug reaction
Neonatal: GA at delivery, BW, sepsis, perinatal mortality, length of level 2 and 3 nursery
care
Notes Pre-trial sample size estimation indicated that 57 participants were required in each arm.
Additional information on the 14 exclusions (5 antibiotic group, 9 placebo) was received.
Tocolysis was included as part of the study protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer generated randomnumbers list.
”
Allocation concealment (selection bias) Low risk By pharmacist.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled trial using identical ad-
ministration regimens in the 2 study groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not clear, but probably low risk. Placebo-
controlled trial.
Selective reporting (reporting bias) Low risk All expected outcome results reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12% (14 women) post-randomisation ex-
clusions. 2 women withdrew consent, 1
womandelivered for fetal distress, 3women
developed chorioamnionitis, 1 women for
undiagnosed twins, 6 women were ex-
cluded for unknown reasons, 1 woman due
to a pharmacy error. All exclusions men-
tioned
Incomplete outcome data longer term out-
comes (attrition bias)
All outcomes
Unclear risk Not applicable.
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McGregor 1991 (Continued)
Other bias Low risk None apparent.
Newton 1989
Methods Single-centre placebo-controlled randomised clinical trial. San Antonio, Texas, US
Participants 103 women 24-35 weeks’ gestation (mean 31 weeks), in preterm labour, receiving to-
colysis.
Exclusions: ruptured membranes, multiple gestation, suspected fetal compromise and
maternal medical conditions
Interventions IV ampicillin 2 g every 6 h x 12 doses, plus oral erythromycin (333 mg every 8 h x 7
days) or identical placebos
Outcomes Primary outcome: mean GA at delivery, mean BW. Other outcomes -
Maternal: delivery > 36 weeks’ gestation, mean days of prolongation, recurrent preterm
labour
Notes Pre-trial sample size estimation indicated that 50 participants were required in each arm.
8 post-randomisation exclusions. Tocolysis was included as part of the study protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States “assigned randomly in a 1:1 ratio”
but does not state how the random se-
quence was generated
Allocation concealment (selection bias) Low risk By pharmacist.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled trial using identical ad-
ministration regimens in the 2 study groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not clear, but probably low risk. Placebo-
controlled trial.
Selective reporting (reporting bias) Low risk All expected outcome results reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 8% (8 women) post-randomisation exclu-
sions. Only 1 lost to follow-up. 3 women
had additional antibiotics, 2 women de-
livered prior to study commencement, 1
woman withdrew consent, 1 woman to al-
lergic reaction, 1 woman lost to follow-up
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Newton 1989 (Continued)
Incomplete outcome data longer term out-
comes (attrition bias)
All outcomes
Unclear risk Not applicable.
Other bias Low risk None apparent.
Newton 1991
Methods Single-centre placebo-controlled randomised clinical trial. San Antonio, Texas, US
Participants 91 women 24-33 weeks’ gestation (mean 30 weeks) in preterm labour receiving tocol-
ysis. Exclusions: ruptured membranes, suspected fetal compromise, maternal medical
conditions or clinical evidence of maternal infection
Multiple births were included.
Interventions IV ampicillin 2 g/sulbactam 1 g every 6 h x 12 doses plus oral indomethacin (50 mg
load, then 25 mg every 6 h x 7 doses) or corresponding placebos
Outcomes Primary outcomes: mean BW and GA at delivery. Other outcomes -Maternal: infection,
adverse drug reaction.
Neonatal: neonatal morbidity andmortality, BW< 2500 g, delivery > 35 weeks’ gestation
Notes Pre-trial sample size estimation indicated that 49 participants were required in each arm.
5 post-randomisation exclusions. “The enrolment was halted early (91 enrolled vs 98
projected patients) for administrative reasons.” Toclolytics was part of the study protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States “assigned randomly in a 1:1 ratio”
but does not state how the random se-
quence was generated
Allocation concealment (selection bias) Low risk By pharmacist.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled trial using identical ad-
ministration regimens in the 2 study groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not clear, but probably low risk. Placebo-
controlled trial.
Selective reporting (reporting bias) Low risk All expected outcome results reported.
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Newton 1991 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6% (5 women) post-randomisation exclu-
sions. 1 woman delivered pre-study com-
mencement, 1womanwas given additional
antibiotics, 3 women were lost to follow-
up
Incomplete outcome data longer term out-
comes (attrition bias)
All outcomes
Unclear risk Not applicable.
Other bias Low risk None apparent.
Norman 1994
Methods Multicentre placebo-controlled randomised clinical trial across 3 centres in South Africa
Participants 82 women 26-34 weeks’ gestation (mean 31 weeks) in preterm labour receiving tocolysis.
Exclusions: rupturedmembranes, antepartum haemorrhage, infection, maternal medical
conditions, multiple pregnancy
Interventions IV ampicillin 1 g every 6 h x 4 doses followed by oral amoxicillin 500 mg every 8 h x 5
days, plus metronidazole 1 gm stat then 400 mg orally every 8 h for 5 days
Outcomes Primary outcome: perinatal mortality. Other outcomes: Maternal: puerperal infection,
median days of prolongation, adverse drug reaction. Neonatal: mean GA at delivery,
mean BW, neonatal hospital stay, major neonatal morbidity
Notes Multicentre trial - 3 centres. Pre-trial sample size estimation indicated that 220 partici-
pants were required in each group. Study was stopped after 82 women were randomised
because of poor recruitment rates. 4 post-randomisation exclusion. Toclolytics was part
of the study protocol: Indomethacin 100 mg rectally twice daily for 48 h with concomi-
tant hexoprenaline.
Additional information received on methods and data for outcome of prolongation of
pregnancy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Randmisation, based on group sequen-
tial system, was centrally controlled by the
MRC Perinatal Mortality Research Unit
Capetown.“
Allocation concealment (selection bias) Low risk Stated ”opaque, sealed, numbered ran-
domisation envelopes“.
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Norman 1994 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Use of placebo was not reported. stated
”control group received no antibiotics“
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding not reported and no use of
placebo.
Selective reporting (reporting bias) Low risk All expected outcome results reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5% (4 women) post-randomisation exclu-
sion. 2 women due to protocol violation
and 1 woman due to twin pregnancy and 1
woman due to intrauterine death (congen-
ital syphilis)
Incomplete outcome data longer term out-
comes (attrition bias)
All outcomes
Unclear risk Not applicable.
Other bias Unclear risk Following a ”initial analysis’, the study was
stopped early due to difficulty in enrolling
sufficient numbers of women
Oyarzun 1998
Methods Single-centre placebo-controlled randomised clinical trial. Chile
Participants 196 women thought to be in labour between 22 and 36 weeks’ gestation, singleton
pregnancy, with intact membranes, and cervical dilatation < 5 cm
Interventions Oral amoxicillin 250 mg every 8 h and erythromycin 500 mg orally every 6 h for 7 days,
or corresponding placebo
Outcomes Primary outcomes: RDS, prolongation of pregnancy (median days). Other outcomes:
frequency of pretermdelivery <37weeks and<34weeks andperinatalmortality, neonatal
sepsis and other morbidity indices
Notes Pre-trial sample size estimation indicated that for a 30% reduction in RDS ~ 260 partici-
pants were required in each group. 23 post-randomisation exclusions. Study medications
supplied by Laboratorio Chile. Tocolysis and maternal corticosteroids were included as
part of the study protocol
Risk of bias
Bias Authors’ judgement Support for judgement
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Oyarzun 1998 (Continued)
Random sequence generation (selection
bias)
Unclear risk States ’simple randomisation using tables’.
Allocation concealment (selection bias) Unclear risk Details not provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled trial using identical ad-
ministration regimens in the 2 study groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not clear, but probably low risk. Placebo-
controlled trial.
Selective reporting (reporting bias) Low risk All expected outcome results reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12% (23 women) post-randomisation ex-
clusions. 13 women were lost to follow-up
and 10 women did not complete treatment
Incomplete outcome data longer term out-
comes (attrition bias)
All outcomes
Unclear risk Not applicable.
Other bias Low risk None apparent.
Rajaei 2006
Methods Single-centre placebo-controlled randomised clinical trial. Iran
Participants 80 women, with idiopathic preterm labour, between 26-34 weeks - cervical dilatation
greater than 1 cm and less than 5 cm, cervical effacement of equal or more than 80%, 4
uterine contractions in 20 minutes, or 8 in 60 minutes with progressive cervical change
unresponsive to hydration and sedation
Exclusions: 1. presence of a recognised cause of preterm labour or obstetric complica-
tion, such as placenta praevia, multiple gestation, abruptio placenta, cervical cerclage,
known uterine or fetal anomaly, pregnancy-induced hypertension, premature rupture of
membranes, intrauterine fetal death or fetal growth retardation. 2. known or suspected
infection such chorioamnionitis, urinary tract infection, pneumonia. 3. fetal indication
for delivery 4. clinically significant maternal cardiac, respiratory, liver, renal or immuno-
logic disease 5. use of antibiotics within 2 weeks of commencement of study
Interventions 400 mg erythromycin or an identical-appearing placebo tablet every 6 h for 10 days
Outcomes Primary: interval to delivery, prolonging pregnancy.
Other outcomes: GA at delivery, mean BW, neonatal admission to NICU
Notes Tocolysis and maternal corticosteroids were included as part of the study protocol
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Rajaei 2006 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Nomention of sequence generation. stated
“assigned randomly”
Allocation concealment (selection bias) Unclear risk Sealed envelopes - whether opaque or se-
quentially numbered not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled trial using identical ad-
ministration regimens in the 2 study groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not clear, but probably low risk. Placebo-
controlled trial.
Selective reporting (reporting bias) Unclear risk Pre-specified trial outcome measures were
not detailed. Neonatal outcomes were not
reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 94 enrolled - 14 patients excluded from
analysis (15%) (9due topregnancy compli-
cations fetal distress, pre-eclampsia, vagi-
nal bleeding, chorioamnionitis); 3 received
wrong doses of treatment, 5 had were lost
to follow-up and 3 stopped medication
Incomplete outcome data longer term out-
comes (attrition bias)
All outcomes
Unclear risk Not applicable.
Other bias Low risk None apparent.
Reimer 1999
Methods Single-centre randomised trial. Germany.
Participants 129 women in preterm labour and with intact membranes.
Interventions Immediate treatment with mezlocillin 2 g IV every 8 h for 3 days
Outcomes Primary: incidence of preterm birth and chorioamnionitis.
Other outcomes: incidence of bacterial vaginosis, use of corticosteroids and tocolytics
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Reimer 1999 (Continued)
Notes No mention of multiple pregnancy or GA at recruitment. No neonatal outcomes re-
ported. Tocolysis and maternal corticosteroids were included as part of the study proto-
col. Authors contacted for additional data and information on study methods
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random numbers generation not de-
scribed. Stated “prospective randomized
trial”
Allocation concealment (selection bias) Unclear risk Stated “those assigned tono antibiotic treat-
ment”.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Use of placebo was not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding not reported and no use of
placebo.
Selective reporting (reporting bias) Unclear risk Neonatal outcomes were not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if there were any lost to follow-up.
Incomplete outcome data longer term out-
comes (attrition bias)
All outcomes
Unclear risk Not applicable.
Other bias Low risk None apparent.
Romero 1993
Methods Multicentre placebo-controlled randomised clinical trial across 4 centres in the US
Participants 277 women 24-34 weeks’ gestation (mean 30.5 weeks) in preterm labour receiving tocol-
ysis. Exclusions: ruptured membranes, multiple pregnancy, suspected fetal compromise,
suspected imminent delivery, suspected maternal infection, recent antibiotic use
Interventions IV ampicillin 1 g every 4 h concomitant IV erythromycin 250 mg every 6 h both for 48
h followed by oral amoxicillin 250 mg every 8 h and erythromycin 333 mg every 8 h for
5 days
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Romero 1993 (Continued)
Outcomes Primary outcomes: days prolongation of pregnancy, frequency of preterm delivery. Sec-
ondary: perinatal mortality and morbidity. Other outcomes - Maternal: adverse drug
reaction, infection, Neonatal: BW, NICU stay
Notes Multicentre trial - 6 centres. Pre-trial sample size estimation indicated that 350 partici-
pants were required for each group. Interim analysis revealed much lower baseline rate
of the neonatal morbidity index than was predicted (14% vs 40%). Trial was halted
after 277 enrolments. 2 post-randomisation exclusions. Additional information on trial
methods were received. Tocolysis and maternal corticosteroids were included as part of
the study protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers.
Allocation concealment (selection bias) Low risk Randomly assigned at an independent cen-
tre using computerised randomisation pro-
cess with stratification by study centre
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled trial using identical ad-
ministration regimens in the 2 study groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not clear, but probably low risk. Placebo-
controlled trial.
Selective reporting (reporting bias) Low risk All expected outcome results reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk < 2% (4 women) post-randomisation ex-
clusions. 1 woman delivered pre-study
commencement, 1 woman diagnosed with
a urinary tract infection, 2womenwere lost
to follow-up
Incomplete outcome data longer term out-
comes (attrition bias)
All outcomes
Unclear risk Not applicable.
Other bias Low risk None apparent.
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Svare 1997
Methods Multicentre placebo-controlled randomised clinical trial across 6 centres in Denmark
Participants 112 women thought to be in labour between 26 and 34 weeks, singleton pregnancy,
cervical dilatation < 4 cm. Exclusion criteria - suspected chorioamnionitis, severe pre-
eclampsia
Interventions IV ampicillin 2 g every 6 h for 24 h, followed by pivampicillin 500 mg orally for 7 days,
plus IV metronidazole 500 mg every 8 h for 24 h, followed by metronidazole 400 mg
orally every 8 h for 7 days, or identical placebo
Outcomes Primary outcomes: difference in median days of prolongation of pregnancy of 8 days,
difference in mean BW of 200 g. Other outcomes: clinical chorioamnionitis, preterm
birth < 37 weeks, Apgar scores, admissions to NICU, days on ventilation, neonatal sepsis
Notes Multicentre trial - 6 centres. Pre-trial sample size estimation indicated that 200 partici-
pants were required. The study was stopped just over half-way because of poor recruit-
ment (110 recruited). 2 post-randomisation exclusions. Also presented were results for
eligible women not included, who were of higher GA, raising a concern about general-
isability
Study medications supplied by LEO Pharmaceutical Products, Copenhagen, Denmark.
Additional data and information received from the author. Tocolysis and maternal cor-
ticosteroids were included as part of the study protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated numbers stratified by
centre.
Allocation concealment (selection bias) Low risk Block randomisation by pharmaceutical
company using consecutively numbered
identical packages
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled trial using identical ad-
ministration regimens in the 2 study groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated “those assessing the outcomes were
blinded to the allocation”
Selective reporting (reporting bias) Low risk All expected outcome results reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk < 2 % (2 women) post-randomisation ex-
clusions. 1 woman had a twin pregnancy
and 1 woman did not receive any treatment
and allocation code could not be found
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Svare 1997 (Continued)
Incomplete outcome data longer term out-
comes (attrition bias)
All outcomes
Unclear risk Not applicable.
Other bias Low risk None apparent.
Watts 1994
Methods Single-centre randomised trial. Washington, Seattle, US.
Participants 56 women < 34 weeks’ gestation (mean 31 weeks) in preterm labour receiving tocolysis.
Exclusions: ruptured membranes, multiple pregnancy, antibiotics within 7 days, cervical
dilatation > 4 cm, rupturedmembranes, maternal infection, maternal medical conditions
Interventions IV mezlocillin 3 g IV every 6 h for 5 days and oral erythromycin 333 mg every 8 h for
10 days
Outcomes Primary: latency, and BW. Secondary: mean BW, mean GA, maternal infection, pro-
longation of pregnancy > 7 days, maternal adverse drug reaction, neonatal antibiotic
therapy, RDS, hospital stay, Apgar scores, perinatal mortality
Notes No pre-trial power calculations.
Additional information and data for the outcome of prolongation of pregnancy were
received
Partly sponsored by Miles Pharmaceutical Co., Inc. Amniocentesis for lung maturity
where possible. women. Tocolysis was were included as part of the study protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not mentioned.
Allocation concealment (selection bias) Unclear risk Stated “Randomly assigned in a blinded
fashion”.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled trial using identical ad-
ministration regimens in the 2 study groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not clear, but probably low risk. Placebo-
controlled trial.
Selective reporting (reporting bias) Low risk All expected outcome results reported.
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Watts 1994 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up.
Incomplete outcome data longer term out-
comes (attrition bias)
All outcomes
Unclear risk Not applicable.
Other bias Low risk None apparent.
BW: birthweight
GA: gestational age
GBS: Group B Streptococcus
h: hour(s)
IV: intravenously
NEC: necrotising enterocolitis
NICU: neonatal intensive care unit
PROM: premature rupture of membranes
RDS: respiratory distress syndrome
stat: immediately
vs: versus
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Gurbuz 2004 Additional information on methods and outcomes to assess eligibility was requested from the authors and had
not been forthcoming at the time of the review
Hensen 1987 Personal communication on a planned trial. Unable to locate publication or author
Lauterbach 2012 The intervention in this trial was not an antibiotic.
McCaul 1992 The authors had not provided information on the 47% post-randomisation exclusions at the time of the review
McGregor 1986 The authors had not provided information on the 36% post-randomisation exclusions at the time of the review
McGregor 1988 Women were not in labour.
Morales 1988 The authors had not provided information on the 27% post-randomisation exclusions at the time of the review
Nadisauskiene 1996 Included women with ruptured membranes.
Naef 1994 Included women with ruptured membranes.
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(Continued)
Ogasawara 1996 Included women with rupture membranes.
Oszukowski 2000 Abstract only with insufficient information on methods and outcomes to enable assessment. Authors were
contacted with no response
Ovalle 2006 Quasi-random method of treatment allocation was used.
Ozden 2000 Quasi-random method of treatment allocation was used.
Purwar 1997 Abstract only. Included women with ruptured membranes.
Saez-Llorens 1995 Quasi-random method of treatment allocation was used.
Winkler 1988 Included women with ruptured membranes.
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D A T A A N D A N A L Y S E S
Comparison 1. Any antibiotics versus no antibiotics
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Perinatal mortality 10 7304 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.88, 1.69]
2 Stillbirth 8 7080 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.43, 1.26]
3 Neonatal death 9 7248 Risk Ratio (M-H, Fixed, 95% CI) 1.57 [1.03, 2.40]
4 Infant death 1 4654 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.68, 1.67]
5 Any functional impairment at 7
years of age.
1 3052 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.99, 1.23]
6 Moderate/severe functional
impairment at 7 years of age.
1 3052 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.89, 1.28]
7 Cerebral palsy at 7 years 1 3173 Risk Ratio (M-H, Fixed, 95% CI) 1.82 [0.99, 3.34]
8 Maternal adverse drug reaction
requiring cessation of treatment
5 626 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.92, 1.89]
9 Maternal infection 10 7371 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.63, 0.86]
10 Delay in birth (subgrouped by
interval)
9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Birth within 48 hours 4 6800 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.89, 1.23]
10.2 Birth within 7 days 8 7053 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.87, 1.10]
11 Interval between randomisation
and birth (days)
6 2499 Mean Difference (IV, Random, 95% CI) 5.59 [0.31, 10.87]
12 Preterm birth (< 36 or < 37
weeks)
10 7387 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.92, 1.05]
13 Gestational age at birth 10 986 Mean Difference (IV, Random, 95% CI) 0.53 [0.00, 1.06]
14 Birthweight 12 7531 Mean Difference (IV, Random, 95% CI) 58.38 [-26.24, 143.
00]
15 Birthweight < 2500 g 5 6628 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.15]
16 Admission to neonatal intensive
or special care nursery
5 6875 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.62, 1.10]
17 Neonatal mechanical
ventilation
1 6241 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.84, 1.24]
18 Respiratory distress syndrome 9 7200 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.84, 1.16]
19 Neonatal positive blood culture 3 6526 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.69, 1.49]
20 Neonatal sepsis 10 7386 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.64, 1.16]
21 Intraventricular haemorrhage 5 6813 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.48, 1.19]
22 Necrotising enterocolitis 6 6880 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.64, 1.73]
23 Major cerebral abnormality 1 6241 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.66, 1.51]
24 Chronic neonatal lung disease 1 6241 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.78, 1.76]
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Comparison 2. Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Perinatal mortality 10 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Beta-lactam antibiotics
alone vs no antibiotics
4 2323 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.64, 2.01]
1.2 Macrolide antibiotics
alone vs no antibiotics
2 2222 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.64, 2.11]
1.3 Macrolide and beta-lactam
antibiotics vs no antibiotics
4 2569 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.79, 2.43]
1.4 Antibiotics active against
anaerobic bacteria vs no
antibiotics
3 294 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [0.36, 7.39]
2 Stillbirth 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Beta-lactam antibiotics
alone vs no antibiotics
4 2323 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.39, 2.14]
2.2 Macrolide antibiotics
alone vs no antibiotics
2 2222 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.20, 1.48]
2.3 Macrolide and beta-lactam
antibiotics vs no antibiotics
2 2347 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.28, 1.90]
2.4 Antibiotics active against
anaerobic bacteria vs no
bacteria
3 294 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Neonatal death 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Beta-lactam antibiotics
alone vs no antibiotics
4 2323 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.61, 2.86]
3.2 Macrolide antibiotics
alone vs no antibiotics
2 2222 Risk Ratio (M-H, Fixed, 95% CI) 1.68 [0.77, 3.64]
3.3 Macrolide and beta-lactam
antibiotics vs no antibiotics
3 2513 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.88, 3.82]
3.4 Antibiotics active against
anaerobic bacteria vs no
antibiotics
3 294 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [0.36, 7.39]
4 Infant death 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Beta-lactam antibiotics
alone vs no antibiotics
1 1515 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.31, 1.65]
4.2 Macrolide antibiotics
alone vs no antibiotics
1 1586 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.53, 2.49]
4.3 Macrolide and beta-lactam
antibiotics vs no antibiotics
1 1553 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.61, 2.81]
4.4 Antibiotics active against
anaerobic bacteria vs no
antibiotics
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Any functional impairment at 7
years of age.
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Beta-lactam antibiotics
alone vs no antibiotics
1 1008 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.87, 1.25]
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5.2 Macrolide antibiotics
alone vs no antibiotics
1 1030 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.94, 1.35]
5.3 Macrolide and beta-lactam
antibiotics vs no antibiotics
1 1014 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.94, 1.35]
5.4 Antibiotics active against
anaerobic bacteria vs no
antibiotics
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Moderate/severe functional
impairment at 7 years of age.
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Beta-lactam antibiotics
alone vs no antibiotics
1 1008 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.75, 1.41]
6.2 Macrolide antibiotics
alone vs no antibiotics
1 1030 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.79, 1.48]
6.3 Macrolide and beta-lactam
antibiotics vs no antibiotics
1 1014 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.82, 1.53]
6.4 Antibiotics active against
anaerobic bacteria vs no
antibiotics
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Cerebral palsy at 7 years of age 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Beta-lactam antibiotics
alone vs no antibiotics
1 1049 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.41, 3.63]
7.2 Macrolide antibiotics
alone vs no antibiotics
1 1073 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.48, 4.15]
7.3 Macrolide and beta-lactam
antibiotics vs no antibiotics
1 1052 Risk Ratio (M-H, Random, 95% CI) 2.83 [1.02, 7.88]
7.4 Antibiotics active against
anaerobic bacteria vs no
antibiotics
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Maternal adverse drug reaction
requiring cessation of treatment
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Beta-lactam antibiotics
alone vs no antibiotics
1 82 Risk Ratio (M-H, Fixed, 95% CI) 3.15 [0.13, 75.05]
8.2 Macrolide antibiotics
alone vs no antibiotics
1 103 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.49, 1.59]
8.3 Macrolide and beta-lactam
antibiotics vs no antibiotics
2 331 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.93, 2.40]
8.4 Antibiotics active against
anaerobic bacteria vs no
antibiotics
2 213 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.59, 1.83]
9 Maternal infection 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Beta-lactam antibiotics
alone vs no antibiotics
4 2385 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.56, 0.97]
9.2 Macrolide antibiotics
alone vs no antibiotics
2 2222 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.62, 1.08]
9.3 Macrolide and beta-lactam
antibiotics vs no antibiotics
4 2563 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.64, 0.98]
9.4 Antibiotics active against
anaerobic bacteria vs no
antibiotics
3 294 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.11, 3.92]
10 Birth within 48 hours of
randomisation
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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10.1 Beta-lactam antibiotics
alone vs no antibiotics
1 2053 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.75, 1.36]
10.2 Macrolide antibiotics
alone vs no antibiotics
1 2119 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.78, 1.42]
10.3 Macrolide and
beta-lactam antibiotics vs no
antibiotics
3 2520 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.86, 1.45]
10.4 Antibiotics active against
anaerobic bacteria vs no
antibiotics
1 109 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.19, 1.57]
11 Interval between randomisation
and birth (days)
7 Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 Beta-lactam antibiotics
alone vs no antibiotics
1 2053 Mean Difference (IV, Random, 95% CI) -0.09 [-2.96, 2.78]
11.2 Macrolide antibiotics
alone vs no antibiotics
3 2302 Mean Difference (IV, Random, 95% CI) 4.26 [-2.88, 11.41]
11.3 Macrolide and
beta-lactam antibiotics vs no
antibiotics
3 2221 Mean Difference (IV, Random, 95% CI) -0.27 [-2.95, 2.41]
11.4 Antibiotics active against
anaerobic bacteria vs no
antibiotics
3 293 Mean Difference (IV, Random, 95% CI) 10.50 [4.95, 16.06]
12 Preterm birth (< 36 or < 37
weeks’ gestation)
10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 Beta-lactam antibiotics
alone vs no antibiotics
5 2430 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.89, 1.10]
12.2 Macrolide antibiotics
alone vs no antibiotics
2 2235 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.91, 1.15]
12.3 Macrolide and
beta-lactam antibiotics vs no
antibiotics
4 2613 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.89, 1.10]
12.4 Antibiotics active against
anaerobic bacteria vs no
antibiotics
2 226 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.53, 1.30]
13 Respiratory distress syndrome 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 Beta-lactam antibiotics
alone vs no antibiotics
3 3278 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.75, 1.16]
13.2 Macrolide antibiotics
alone vs no antibiotics
1 3156 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.75, 1.18]
13.3 Macrolide and
beta-lactam antibiotics vs no
antibiotics
2 3382 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.84, 1.29]
13.4 Antibiotics active against
anaerobic bacteria vs no
antibiotics
1 109 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.10, 3.37]
14 Necrotising enterocolitis 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 Beta-lactam antibiotics
alone vs no antibiotics
3 2227 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.52, 3.32]
14.2 Macrolide antibiotics
alone vs no antibiotics
1 2119 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.44, 3.86]
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14.3 Macrolide and
beta-lactam antibiotics vs no
antibiotics
2 2345 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.60, 3.11]
14.4 Antibiotics active against
anaerobic bacteria vs no
antibiotics
2 190 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.02, 1.01]
15 Intraventricular haemorrhage 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 Beta-lactam antibiotics
alone vs no antibiotics
3 2241 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.38, 1.87]
15.2 Macrolide antibiotics
alone vs no antibiotics
1 2119 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.35, 1.99]
15.3 Macrolide and
beta-lactam antibiotics vs no
antibiotics
2 2345 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.43, 2.19]
15.4 Antibiotics active against
anaerobic bacteria vs no
antibiotics
1 109 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.02, 1.46]
Comparison 3. Any macrolide versus no macrolide
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Perinatal mortality 4 6740 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.89, 1.60]
2 Stillbirth 2 6518 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.41, 1.20]
3 Neonatal death 3 6684 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [1.05, 2.19]
4 Infant death 1 4583 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.99, 2.18]
5 Any functional impairment at 7
years of age.
1 3052 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [1.01, 1.20]
6 Moderate/severe functional
impairment at 7 years of age.
1 3052 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.93, 1.26]
7 Cerebral palsy at 7 years 1 3173 Risk Ratio (M-H, Fixed, 95% CI) 1.90 [1.20, 3.01]
8 Maternal adverse drug reaction
requiring cessation of treatment
2 331 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.93, 2.40]
9 Maternal infection 4 6745 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.41, 1.07]
10 Birth within 48 hours of
randomisation
3 6691 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.94, 1.25]
11 Interval between randomisation
and birth (days)
3 6386 Mean Difference (IV, Random, 95% CI) 1.07 [-3.58, 5.72]
12 Preterm birth (< 36 or < 37
weeks)
4 6784 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
13 Respiratory distress syndrome 4 6740 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.90, 1.21]
14 Intraventricular haemorrhage 2 6516 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.62, 1.49]
15 Necrotising enterocolitis 2 6516 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.74, 1.80]
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Comparison 4. Any beta-lactam versus no beta-lactam
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Perinatal mortality 8 7109 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.84, 1.48]
2 Stillbirth 6 6887 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.76, 1.58]
3 Neonatal death 7 7053 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [1.06, 2.15]
4 Infant death 1 4654 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.64, 1.38]
5 Any functional impairment at 7
years of age.
1 3052 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.93, 1.11]
6 Moderate/severe functional
impairment at 7 years of age.
1 3052 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.88, 1.20]
7 Cerebral palsy at 7 years 1 3173 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [1.06, 2.61]
8 Maternal adverse drug reaction
requiring cessation of treatment
4 523 Risk Ratio (M-H, Fixed, 95% CI) 1.61 [1.02, 2.54]
9 Maternal infection 8 7182 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.69, 0.92]
10 Birth within 48 hours of
randomisation
4 6800 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.89, 1.18]
11 Interval between randomisation
and birth (days)
3 6386 Mean Difference (IV, Random, 95% CI) 3.92 [-5.08, 12.92]
12 Preterm birth (< 36 or < 37
weeks)
8 7185 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.92, 1.04]
13 Respiratory distress syndrome 8 7108 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.88, 1.19]
14 Intraventricular haemorrhage 4 6721 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.56, 1.31]
15 Necrotising enterocolitis 5 6788 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.27, 1.92]
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Analysis 1.1. Comparison 1 Any antibiotics versus no antibiotics, Outcome 1 Perinatal mortality.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 1 Perinatal mortality
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1996 1/40 0/42 0.7 % 3.15 [ 0.13, 75.05 ]
Kenyon 2001a 128/4685 39/1556 89.9 % 1.09 [ 0.77, 1.55 ]
Keuchkerian 2005 1/47 1/49 1.5 % 1.04 [ 0.07, 16.19 ]
McGregor 1991 2/53 0/50 0.8 % 4.72 [ 0.23, 96.01 ]
Newton 1991 2/47 0/45 0.8 % 4.79 [ 0.24, 97.14 ]
Norman 1994 2/43 2/38 3.3 % 0.88 [ 0.13, 5.97 ]
Oyarzun 1998 2/78 1/90 1.4 % 2.31 [ 0.21, 24.97 ]
Romero 1993 2/131 0/144 0.7 % 5.49 [ 0.27, 113.36 ]
Svare 1997 0/59 0/51 Not estimable
Watts 1994 1/30 0/26 0.8 % 2.61 [ 0.11, 61.51 ]
Total (95% CI) 5213 2091 100.0 % 1.22 [ 0.88, 1.69 ]
Total events: 141 (Antibiotics), 43 (No antibiotics)
Heterogeneity: Chi2 = 3.87, df = 8 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Any antibiotics versus no antibiotics, Outcome 2 Stillbirth.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 2 Stillbirth
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1996 0/40 0/42 Not estimable
Kenyon 2001a 37/4685 18/1556 94.8 % 0.68 [ 0.39, 1.20 ]
Keuchkerian 2005 1/47 1/49 3.4 % 1.04 [ 0.07, 16.19 ]
McGregor 1991 0/53 0/50 Not estimable
Newton 1991 1/47 0/45 1.8 % 2.88 [ 0.12, 68.79 ]
Norman 1994 0/43 0/38 Not estimable
Romero 1993 0/131 0/144 Not estimable
Svare 1997 0/59 0/51 Not estimable
Total (95% CI) 5105 1975 100.0 % 0.73 [ 0.43, 1.26 ]
Total events: 39 (Antibiotics), 19 (No antibiotics)
Heterogeneity: Chi2 = 0.84, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Any antibiotics versus no antibiotics, Outcome 3 Neonatal death.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 3 Neonatal death
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1996 1/40 0/42 1.3 % 3.15 [ 0.13, 75.05 ]
Kenyon 2001a 91/4685 21/1556 86.2 % 1.44 [ 0.90, 2.31 ]
Keuchkerian 2005 0/47 0/49 Not estimable
McGregor 1991 2/53 0/50 1.4 % 4.72 [ 0.23, 96.01 ]
Newton 1991 1/47 0/45 1.4 % 2.88 [ 0.12, 68.79 ]
Norman 1994 2/43 2/38 5.8 % 0.88 [ 0.13, 5.97 ]
Oyarzun 1998 2/78 1/90 2.5 % 2.31 [ 0.21, 24.97 ]
Romero 1993 2/131 0/144 1.3 % 5.49 [ 0.27, 113.36 ]
Svare 1997 0/59 0/51 Not estimable
Total (95% CI) 5183 2065 100.0 % 1.57 [ 1.03, 2.40 ]
Total events: 101 (Antibiotics), 24 (No antibiotics)
Heterogeneity: Chi2 = 2.07, df = 6 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Any antibiotics versus no antibiotics, Outcome 4 Infant death.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 4 Infant death
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 78/3508 24/1146 100.0 % 1.06 [ 0.68, 1.67 ]
Total (95% CI) 3508 1146 100.0 % 1.06 [ 0.68, 1.67 ]
Total events: 78 (Antibiotics), 24 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Any antibiotics versus no antibiotics, Outcome 5 Any functional impairment at
7 years of age..
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 5 Any functional impairment at 7 years of age.
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 957/2317 275/735 100.0 % 1.10 [ 0.99, 1.23 ]
Total (95% CI) 2317 735 100.0 % 1.10 [ 0.99, 1.23 ]
Total events: 957 (Antibiotics), 275 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Any antibiotics versus no antibiotics, Outcome 6 Moderate/severe functional
impairment at 7 years of age..
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 6 Moderate/severe functional impairment at 7 years of age.
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 417/2317 124/735 100.0 % 1.07 [ 0.89, 1.28 ]
Total (95% CI) 2317 735 100.0 % 1.07 [ 0.89, 1.28 ]
Total events: 417 (Antibiotics), 124 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Any antibiotics versus no antibiotics, Outcome 7 Cerebral palsy at 7 years.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 7 Cerebral palsy at 7 years
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 68/2403 12/770 100.0 % 1.82 [ 0.99, 3.34 ]
Total (95% CI) 2403 770 100.0 % 1.82 [ 0.99, 3.34 ]
Total events: 68 (Antibiotics), 12 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours antibiotics Favours no antibiotics
53Prophylactic antibiotics for inhibiting preterm labour with intact membranes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.8. Comparison 1 Any antibiotics versus no antibiotics, Outcome 8 Maternal adverse drug
reaction requiring cessation of treatment.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 8 Maternal adverse drug reaction requiring cessation of treatment
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1996 1/40 0/42 1.2 % 3.15 [ 0.13, 75.05 ]
McGregor 1991 15/53 16/50 39.8 % 0.88 [ 0.49, 1.59 ]
Romero 1993 27/131 20/144 46.1 % 1.48 [ 0.88, 2.52 ]
Svare 1997 4/59 1/51 2.6 % 3.46 [ 0.40, 29.95 ]
Watts 1994 7/30 4/26 10.4 % 1.52 [ 0.50, 4.60 ]
Total (95% CI) 313 313 100.0 % 1.32 [ 0.92, 1.89 ]
Total events: 54 (Antibiotics), 41 (No antibiotics)
Heterogeneity: Chi2 = 3.08, df = 4 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Any antibiotics versus no antibiotics, Outcome 9 Maternal infection.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 9 Maternal infection
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gordon 1995 2/58 3/59 0.9 % 0.68 [ 0.12, 3.91 ]
Kenyon 2001a 433/4685 183/1556 83.8 % 0.79 [ 0.67, 0.92 ]
McGregor 1991 1/53 3/50 0.9 % 0.31 [ 0.03, 2.92 ]
Newton 1991 1/43 6/43 1.8 % 0.17 [ 0.02, 1.33 ]
Norman 1994 1/43 3/38 1.0 % 0.29 [ 0.03, 2.71 ]
Oyarzun 1998 5/83 8/90 2.3 % 0.68 [ 0.23, 1.99 ]
Reimer 1999 2/61 6/68 1.7 % 0.37 [ 0.08, 1.77 ]
Romero 1993 7/131 14/144 4.1 % 0.55 [ 0.23, 1.32 ]
Svare 1997 3/59 0/51 0.2 % 6.07 [ 0.32, 114.74 ]
Watts 1994 3/30 10/26 3.3 % 0.26 [ 0.08, 0.84 ]
Total (95% CI) 5246 2125 100.0 % 0.74 [ 0.63, 0.86 ]
Total events: 458 (Antibiotics), 236 (No antibiotics)
Heterogeneity: Chi2 = 9.96, df = 9 (P = 0.35); I2 =10%
Test for overall effect: Z = 3.91 (P = 0.000090)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Any antibiotics versus no antibiotics, Outcome 10 Delay in birth (subgrouped
by interval).
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 10 Delay in birth (subgrouped by interval)
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Birth within 48 hours
Kenyon 2001a 478/4685 152/1556 88.2 % 1.04 [ 0.88, 1.24 ]
Oyarzun 1998 12/83 13/90 4.8 % 1.00 [ 0.48, 2.07 ]
Romero 1993 14/133 10/144 3.7 % 1.52 [ 0.70, 3.30 ]
Svare 1997 5/58 8/51 3.3 % 0.55 [ 0.19, 1.57 ]
Subtotal (95% CI) 4959 1841 100.0 % 1.04 [ 0.89, 1.23 ]
Total events: 509 (Antibiotics), 183 (No antibiotics)
Heterogeneity: Chi2 = 2.33, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Birth within 7 days
Cox 1996 13/39 14/39 3.0 % 0.93 [ 0.50, 1.71 ]
Gordon 1995 6/58 9/59 1.9 % 0.68 [ 0.26, 1.78 ]
Kenyon 2001a 724/4685 237/1556 76.9 % 1.01 [ 0.89, 1.16 ]
Keuchkerian 2005 4/47 5/49 1.1 % 0.83 [ 0.24, 2.92 ]
Norman 1994 16/43 23/38 5.3 % 0.61 [ 0.39, 0.98 ]
Romero 1993 29/131 24/144 4.9 % 1.33 [ 0.82, 2.16 ]
Svare 1997 12/58 17/51 3.9 % 0.62 [ 0.33, 1.17 ]
Watts 1994 13/30 13/26 3.0 % 0.87 [ 0.49, 1.52 ]
Subtotal (95% CI) 5091 1962 100.0 % 0.98 [ 0.87, 1.10 ]
Total events: 817 (Antibiotics), 342 (No antibiotics)
Heterogeneity: Chi2 = 8.41, df = 7 (P = 0.30); I2 =17%
Test for overall effect: Z = 0.37 (P = 0.71)
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Analysis 1.11. Comparison 1 Any antibiotics versus no antibiotics, Outcome 11 Interval between
randomisation and birth (days).
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 11 Interval between randomisation and birth (days)
Study or subgroup Antibiotcs No antibiotics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kenyon 2001a 1551 43.86 (29.29) 519 44.08 (28.91) 26.5 % -0.22 [ -3.10, 2.66 ]
McGregor 1991 53 35.3 (24.1) 50 25.4 (20) 16.4 % 9.90 [ 1.37, 18.43 ]
Norman 1994 43 23.5 (24.2) 38 16 (22) 14.1 % 7.50 [ -2.56, 17.56 ]
Rajaei 2006 38 33.33 (18.36) 42 26.88 (13.9) 18.8 % 6.45 [ -0.74, 13.64 ]
Svare 1997 58 43.9 (30.7) 51 29.1 (26) 13.3 % 14.80 [ 4.15, 25.45 ]
Watts 1994 30 21.4 (22) 26 23.3 (25.3) 11.0 % -1.90 [ -14.41, 10.61 ]
Total (95% CI) 1773 726 100.0 % 5.59 [ 0.31, 10.87 ]
Heterogeneity: Tau2 = 25.22; Chi2 = 14.01, df = 5 (P = 0.02); I2 =64%
Test for overall effect: Z = 2.07 (P = 0.038)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Any antibiotics versus no antibiotics, Outcome 12 Preterm birth (< 36 or < 37
weeks).
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 12 Preterm birth (< 36 or < 37 weeks)
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1996 23/39 22/39 1.9 % 1.05 [ 0.71, 1.53 ]
Gordon 1995 35/58 34/59 2.9 % 1.05 [ 0.77, 1.42 ]
Kenyon 2001a 1687/4685 559/1556 73.1 % 1.00 [ 0.93, 1.08 ]
Keuchkerian 2005 17/47 19/49 1.6 % 0.93 [ 0.56, 1.57 ]
McGregor 1991 38/58 37/58 3.2 % 1.03 [ 0.78, 1.34 ]
Newton 1989 18/48 21/47 1.8 % 0.84 [ 0.52, 1.36 ]
Newton 1991 23/43 27/43 2.4 % 0.85 [ 0.59, 1.22 ]
Oyarzun 1998 38/83 45/90 3.8 % 0.92 [ 0.67, 1.25 ]
Romero 1993 69/131 74/144 6.1 % 1.02 [ 0.82, 1.29 ]
Svare 1997 25/59 33/51 3.1 % 0.65 [ 0.46, 0.94 ]
Total (95% CI) 5251 2136 100.0 % 0.98 [ 0.92, 1.05 ]
Total events: 1973 (Antibiotics), 871 (No antibiotics)
Heterogeneity: Chi2 = 6.89, df = 9 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Any antibiotics versus no antibiotics, Outcome 13 Gestational age at birth.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 13 Gestational age at birth
Study or subgroup Antibiotics No antibiotics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cox 1996 39 34.2 (4.43) 39 34.1 (3.88) 6.2 % 0.10 [ -1.75, 1.95 ]
Gordon 1995 58 36 (2.9) 59 35.9 (2.9) 12.8 % 0.10 [ -0.95, 1.15 ]
Keuchkerian 2005 47 37.41 (2.73) 49 37.18 (3.19) 11.3 % 0.23 [ -0.96, 1.42 ]
McGregor 1991 53 35.4 (3.2) 50 34.9 (3.3) 10.5 % 0.50 [ -0.76, 1.76 ]
Newton 1989 48 36.8 (2.9) 47 36.8 (2.8) 11.7 % 0.0 [ -1.15, 1.15 ]
Norman 1994 43 34.3 (3.3) 38 33.1 (3.8) 7.9 % 1.20 [ -0.36, 2.76 ]
Oyarzun 1998 80 31.8 (3.6) 90 32.03 (2.27) 14.6 % -0.23 [ -1.15, 0.69 ]
Rajaei 2006 38 36.11 (2.32) 42 34.36 (2.33) 13.2 % 1.75 [ 0.73, 2.77 ]
Svare 1997 59 36.2 (4.3) 51 34.1 (4.4) 7.4 % 2.10 [ 0.47, 3.73 ]
Watts 1994 30 33.1 (4.8) 26 33.5 (4.1) 4.3 % -0.40 [ -2.73, 1.93 ]
Total (95% CI) 495 491 100.0 % 0.53 [ 0.00, 1.06 ]
Heterogeneity: Tau2 = 0.27; Chi2 = 14.91, df = 9 (P = 0.09); I2 =40%
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Any antibiotics versus no antibiotics, Outcome 14 Birthweight.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 14 Birthweight
Study or subgroup Antibiotics Controls
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cox 1996 40 2394 (790) 42 2225 (758) 4.9 % 169.00 [ -166.39, 504.39 ]
Gordon 1995 70 2660 (750) 69 2634 (691) 7.8 % 26.00 [ -213.69, 265.69 ]
Kenyon 2001a 4685 2839 (797) 1556 2857 (775) 19.8 % -18.00 [ -62.76, 26.76 ]
Keuchkerian 2005 47 3004 (491.1) 49 2972 (450.3) 10.3 % 32.00 [ -156.70, 220.70 ]
McGregor 1991 53 2568 (643) 50 2441 (694) 7.1 % 127.00 [ -131.79, 385.79 ]
Newton 1989 48 2855 (667) 47 2847 (609) 7.2 % 8.00 [ -248.74, 264.74 ]
Norman 1994 43 2318 (609) 38 2093 (653) 6.5 % 225.00 [ -51.11, 501.11 ]
Oyarzun 1998 83 2879 (723) 90 2942 (676) 9.2 % -63.00 [ -272.04, 146.04 ]
Rajaei 2006 38 2792 (511.65) 42 2419 (513.54) 8.4 % 373.00 [ 148.09, 597.91 ]
Romero 1993 131 2535 (790) 144 2683 (720) 10.8 % -148.00 [ -327.25, 31.25 ]
Svare 1997 59 2662 (842) 51 2370 (900) 5.1 % 292.00 [ -35.37, 619.37 ]
Watts 1994 30 2202 (851) 26 2212 (862) 3.0 % -10.00 [ -460.02, 440.02 ]
Total (95% CI) 5327 2204 100.0 % 58.38 [ -26.24, 143.00 ]
Heterogeneity: Tau2 = 8895.21; Chi2 = 21.78, df = 11 (P = 0.03); I2 =49%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Any antibiotics versus no antibiotics, Outcome 15 Birthweight < 2500 g.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 15 Birthweight < 2500 g
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cox 1996 21/40 26/42 14.8 % 0.85 [ 0.58, 1.24 ]
Kenyon 2001a 1342/4685 419/1556 41.2 % 1.06 [ 0.97, 1.17 ]
McGregor 1991 21/53 26/50 12.6 % 0.76 [ 0.50, 1.17 ]
Newton 1991 31/45 26/47 18.2 % 1.25 [ 0.90, 1.72 ]
Svare 1997 23/59 27/51 13.2 % 0.74 [ 0.49, 1.11 ]
Total (95% CI) 4882 1746 100.0 % 0.97 [ 0.81, 1.15 ]
Total events: 1438 (Antibiotics), 524 (No antibiotics)
Heterogeneity: Tau2 = 0.02; Chi2 = 7.29, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Any antibiotics versus no antibiotics, Outcome 16 Admission to neonatal
intensive or special care nursery.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 16 Admission to neonatal intensive or special care nursery
Study or subgroup Any antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kenyon 2001a 1216/4685 380/1556 32.7 % 1.06 [ 0.96, 1.17 ]
Oyarzun 1998 5/78 10/90 6.3 % 0.58 [ 0.21, 1.62 ]
Rajaei 2006 13/38 25/42 16.5 % 0.57 [ 0.35, 0.95 ]
Romero 1993 44/133 46/144 23.1 % 1.04 [ 0.74, 1.45 ]
Svare 1997 23/58 32/51 21.3 % 0.63 [ 0.43, 0.93 ]
Total (95% CI) 4992 1883 100.0 % 0.82 [ 0.62, 1.10 ]
Total events: 1301 (Any antibiotic), 493 (No antibiotic)
Heterogeneity: Tau2 = 0.06; Chi2 = 12.76, df = 4 (P = 0.01); I2 =69%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Any antibiotics versus no antibiotics, Outcome 17 Neonatal mechanical
ventilation.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 17 Neonatal mechanical ventilation
Study or subgroup Any antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 371/4685 121/1556 100.0 % 1.02 [ 0.84, 1.24 ]
Total (95% CI) 4685 1556 100.0 % 1.02 [ 0.84, 1.24 ]
Total events: 371 (Any antibiotic), 121 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Any antibiotics versus no antibiotics, Outcome 18 Respiratory distress
syndrome.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 18 Respiratory distress syndrome
Study or subgroup Any antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1996 8/40 8/42 2.9 % 1.05 [ 0.44, 2.53 ]
Kenyon 2001a 399/4685 138/1556 77.8 % 0.96 [ 0.80, 1.16 ]
Keuchkerian 2005 3/47 3/49 1.1 % 1.04 [ 0.22, 4.91 ]
Newton 1991 12/47 13/45 5.0 % 0.88 [ 0.45, 1.73 ]
Norman 1994 3/43 6/38 2.4 % 0.44 [ 0.12, 1.65 ]
Oyarzun 1998 9/78 7/90 2.4 % 1.48 [ 0.58, 3.80 ]
Romero 1993 14/131 11/144 3.9 % 1.40 [ 0.66, 2.97 ]
Svare 1997 2/58 3/51 1.2 % 0.59 [ 0.10, 3.37 ]
Watts 1994 13/30 8/26 3.2 % 1.41 [ 0.69, 2.86 ]
Total (95% CI) 5159 2041 100.0 % 0.99 [ 0.84, 1.16 ]
Total events: 463 (Any antibiotic), 197 (No antibiotic)
Heterogeneity: Chi2 = 4.50, df = 8 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Any antibiotics versus no antibiotics, Outcome 19 Neonatal positive blood
culture.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 19 Neonatal positive blood culture
Study or subgroup Any antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gordon 1995 2/58 2/59 3.9 % 1.02 [ 0.15, 6.98 ]
Kenyon 2001a 96/4685 31/1556 92.4 % 1.03 [ 0.69, 1.54 ]
Oyarzun 1998 1/78 2/90 3.7 % 0.58 [ 0.05, 6.24 ]
Total (95% CI) 4821 1705 100.0 % 1.01 [ 0.69, 1.49 ]
Total events: 99 (Any antibiotic), 35 (No antibiotic)
Heterogeneity: Chi2 = 0.22, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Any antibiotics versus no antibiotics, Outcome 20 Neonatal sepsis.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 20 Neonatal sepsis
Study or subgroup Any antibiotic No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1996 1/40 0/42 0.5 % 3.15 [ 0.13, 75.05 ]
Gordon 1995 2/70 2/69 2.2 % 0.99 [ 0.14, 6.80 ]
Kenyon 2001a 96/4685 31/1556 50.7 % 1.03 [ 0.69, 1.54 ]
Keuchkerian 2005 0/47 0/49 Not estimable
McGregor 1991 2/53 4/50 4.5 % 0.47 [ 0.09, 2.46 ]
Newton 1991 1/47 1/45 1.1 % 0.96 [ 0.06, 14.85 ]
Norman 1994 4/43 4/38 4.6 % 0.88 [ 0.24, 3.29 ]
Oyarzun 1998 1/78 8/90 8.1 % 0.14 [ 0.02, 1.13 ]
Romero 1993 14/131 15/144 15.6 % 1.03 [ 0.52, 2.04 ]
Svare 1997 6/58 11/51 12.7 % 0.48 [ 0.19, 1.20 ]
Total (95% CI) 5252 2134 100.0 % 0.86 [ 0.64, 1.16 ]
Total events: 127 (Any antibiotic), 76 (No antibiotics)
Heterogeneity: Chi2 = 6.62, df = 8 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 Any antibiotics versus no antibiotics, Outcome 21 Intraventricular
haemorrhage.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 21 Intraventricular haemorrhage
Study or subgroup Any antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 55/4685 22/1556 79.9 % 0.83 [ 0.51, 1.36 ]
Keuchkerian 2005 0/47 0/49 Not estimable
Newton 1991 2/47 2/45 4.9 % 0.96 [ 0.14, 6.51 ]
Romero 1993 1/131 1/144 2.3 % 1.10 [ 0.07, 17.40 ]
Svare 1997 1/58 5/51 12.9 % 0.18 [ 0.02, 1.46 ]
Total (95% CI) 4968 1845 100.0 % 0.76 [ 0.48, 1.19 ]
Total events: 59 (Any antibiotic), 30 (No antibiotic)
Heterogeneity: Chi2 = 2.09, df = 3 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Any antibiotics versus no antibiotics, Outcome 22 Necrotising enterocolitis.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 22 Necrotising enterocolitis
Study or subgroup Any antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1996 0/40 1/42 4.5 % 0.35 [ 0.01, 8.34 ]
Kenyon 2001a 58/4685 12/1556 55.1 % 1.61 [ 0.86, 2.98 ]
Newton 1991 1/47 1/45 3.1 % 0.96 [ 0.06, 14.85 ]
Norman 1994 0/43 5/38 17.8 % 0.08 [ 0.00, 1.41 ]
Romero 1993 3/131 5/144 14.6 % 0.66 [ 0.16, 2.71 ]
Svare 1997 0/58 1/51 4.9 % 0.29 [ 0.01, 7.06 ]
Total (95% CI) 5004 1876 100.0 % 1.06 [ 0.64, 1.73 ]
Total events: 62 (Any antibiotic), 25 (No antibiotic)
Heterogeneity: Chi2 = 6.38, df = 5 (P = 0.27); I2 =22%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 1.23. Comparison 1 Any antibiotics versus no antibiotics, Outcome 23 Major cerebral abnormality.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 23 Major cerebral abnormality
Study or subgroup Any antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 87/4685 29/1556 100.0 % 1.00 [ 0.66, 1.51 ]
Total (95% CI) 4685 1556 100.0 % 1.00 [ 0.66, 1.51 ]
Total events: 87 (Any antibiotics), 29 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 1.24. Comparison 1 Any antibiotics versus no antibiotics, Outcome 24 Chronic neonatal lung
disease.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 1 Any antibiotics versus no antibiotics
Outcome: 24 Chronic neonatal lung disease
Study or subgroup Any antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 102/4685 29/1556 100.0 % 1.17 [ 0.78, 1.76 ]
Total (95% CI) 4685 1556 100.0 % 1.17 [ 0.78, 1.76 ]
Total events: 102 (Any antibiotic), 29 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours any antibiotic Favours no antibiotic
69Prophylactic antibiotics for inhibiting preterm labour with intact membranes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome 1
Perinatal mortality.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 1 Perinatal mortality
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beta-lactam antibiotics alone vs no antibiotics
Cox 1996 1/40 0/42 2.3 % 3.15 [ 0.13, 75.05 ]
Kenyon 2001a 38/1534 13/519 90.8 % 0.99 [ 0.53, 1.84 ]
Keuchkerian 2005 1/47 1/49 4.6 % 1.04 [ 0.07, 16.19 ]
Newton 1991 2/47 0/45 2.4 % 4.79 [ 0.24, 97.14 ]
Subtotal (95% CI) 1668 655 100.0 % 1.13 [ 0.64, 2.01 ]
Total events: 42 (Antibiotics), 14 (No antibiotics)
Heterogeneity: Chi2 = 1.47, df = 3 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
2 Macrolide antibiotics alone vs no antibiotics
Kenyon 2001a 43/1600 13/519 97.4 % 1.07 [ 0.58, 1.98 ]
McGregor 1991 2/53 0/50 2.6 % 4.72 [ 0.23, 96.01 ]
Subtotal (95% CI) 1653 569 100.0 % 1.17 [ 0.64, 2.11 ]
Total events: 45 (Antibiotics), 13 (No antibiotics)
Heterogeneity: Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Kenyon 2001a 47/1551 13/519 90.9 % 1.21 [ 0.66, 2.22 ]
Oyarzun 1998 2/78 1/90 4.3 % 2.31 [ 0.21, 24.97 ]
Romero 1993 2/131 0/144 2.2 % 5.49 [ 0.27, 113.36 ]
Watts 1994 1/30 0/26 2.5 % 2.61 [ 0.11, 61.51 ]
Subtotal (95% CI) 1790 779 100.0 % 1.39 [ 0.79, 2.43 ]
Total events: 52 (Antibiotics), 14 (No antibiotics)
Heterogeneity: Chi2 = 1.32, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
4 Antibiotics active against anaerobic bacteria vs no antibiotics
McGregor 1991 2/53 0/50 19.5 % 4.72 [ 0.23, 96.01 ]
Norman 1994 2/43 2/38 80.5 % 0.88 [ 0.13, 5.97 ]
Svare 1997 0/59 0/51 Not estimable
Subtotal (95% CI) 155 139 100.0 % 1.63 [ 0.36, 7.39 ]
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(. . . Continued)
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 4 (Antibiotics), 2 (No antibiotics)
Heterogeneity: Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.42, df = 3 (P = 0.94), I2 =0.0%
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Analysis 2.2. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome 2
Stillbirth.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 2 Stillbirth
Study or subgroup Antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beta-lactam antibiotics alone vs no antibiotics
Cox 1996 0/40 0/42 Not estimable
Kenyon 2001a 14/1534 6/519 85.8 % 0.79 [ 0.30, 2.04 ]
Keuchkerian 2005 1/47 1/49 9.4 % 1.04 [ 0.07, 16.19 ]
Newton 1991 1/47 0/45 4.9 % 2.88 [ 0.12, 68.79 ]
Subtotal (95% CI) 1668 655 100.0 % 0.91 [ 0.39, 2.14 ]
Total events: 16 (Antibiotic), 7 (No antibiotic)
Heterogeneity: Chi2 = 0.60, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
2 Macrolide antibiotics alone vs no antibiotics
Kenyon 2001a 10/1600 6/519 100.0 % 0.54 [ 0.20, 1.48 ]
McGregor 1991 0/53 0/50 Not estimable
Subtotal (95% CI) 1653 569 100.0 % 0.54 [ 0.20, 1.48 ]
Total events: 10 (Antibiotic), 6 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
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(. . . Continued)
Study or subgroup Antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Kenyon 2001a 13/1551 6/519 100.0 % 0.73 [ 0.28, 1.90 ]
Romero 1993 0/133 0/144 Not estimable
Subtotal (95% CI) 1684 663 100.0 % 0.73 [ 0.28, 1.90 ]
Total events: 13 (Antibiotic), 6 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
4 Antibiotics active against anaerobic bacteria vs no bacteria
McGregor 1991 0/53 0/50 Not estimable
Norman 1994 0/43 0/38 Not estimable
Svare 1997 0/59 0/51 Not estimable
Subtotal (95% CI) 155 139 Not estimable
Total events: 0 (Antibiotic), 0 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.61, df = 2 (P = 0.74), I2 =0.0%
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Analysis 2.3. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome 3
Neonatal death.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 3 Neonatal death
Study or subgroup Antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beta-lactam antibiotics alone vs no antibiotics
Cox 1996 1/40 0/42 4.3 % 3.15 [ 0.13, 75.05 ]
Kenyon 2001a 24/1534 7/519 91.3 % 1.16 [ 0.50, 2.68 ]
Keuchkerian 2005 0/47 0/49 Not estimable
Newton 1991 1/47 0/45 4.5 % 2.88 [ 0.12, 68.79 ]
Subtotal (95% CI) 1668 655 100.0 % 1.32 [ 0.61, 2.86 ]
Total events: 26 (Antibiotic), 7 (No antibiotic)
Heterogeneity: Chi2 = 0.61, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
2 Macrolide antibiotics alone vs no antibiotics
Kenyon 2001a 33/1600 7/519 95.4 % 1.53 [ 0.68, 3.44 ]
McGregor 1991 2/53 0/50 4.6 % 4.72 [ 0.23, 96.01 ]
Subtotal (95% CI) 1653 569 100.0 % 1.68 [ 0.77, 3.64 ]
Total events: 35 (Antibiotic), 7 (No antibiotic)
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Kenyon 2001a 34/1551 7/519 88.2 % 1.63 [ 0.72, 3.64 ]
Oyarzun 1998 2/78 1/90 7.8 % 2.31 [ 0.21, 24.97 ]
Romero 1993 2/131 0/144 4.0 % 5.49 [ 0.27, 113.36 ]
Subtotal (95% CI) 1760 753 100.0 % 1.83 [ 0.88, 3.82 ]
Total events: 38 (Antibiotic), 8 (No antibiotic)
Heterogeneity: Chi2 = 0.63, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.10)
4 Antibiotics active against anaerobic bacteria vs no antibiotics
McGregor 1991 2/53 0/50 19.5 % 4.72 [ 0.23, 96.01 ]
Norman 1994 2/43 2/38 80.5 % 0.88 [ 0.13, 5.97 ]
Svare 1997 0/59 0/51 Not estimable
Subtotal (95% CI) 155 139 100.0 % 1.63 [ 0.36, 7.39 ]
Total events: 4 (Antibiotic), 2 (No antibiotic)
Heterogeneity: Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.38, df = 3 (P = 0.94), I2 =0.0%
0.01 0.1 1 10 100
Favours antibiotic Favours no antibiotic
73Prophylactic antibiotics for inhibiting preterm labour with intact membranes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.4. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome 4
Infant death.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 4 Infant death
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beta-lactam antibiotics alone vs no antibiotics
Kenyon 2001a 17/1133 8/382 100.0 % 0.72 [ 0.31, 1.65 ]
Subtotal (95% CI) 1133 382 100.0 % 0.72 [ 0.31, 1.65 ]
Total events: 17 (Antibiotics), 8 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
2 Macrolide antibiotics alone vs no antibiotics
Kenyon 2001a 29/1204 8/382 100.0 % 1.15 [ 0.53, 2.49 ]
Subtotal (95% CI) 1204 382 100.0 % 1.15 [ 0.53, 2.49 ]
Total events: 29 (Antibiotics), 8 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Kenyon 2001a 32/1171 8/382 100.0 % 1.30 [ 0.61, 2.81 ]
Subtotal (95% CI) 1171 382 100.0 % 1.30 [ 0.61, 2.81 ]
Total events: 32 (Antibiotics), 8 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
4 Antibiotics active against anaerobic bacteria vs no antibiotics
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antibiotics), 0 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 1.17, df = 2 (P = 0.56), I2 =0.0%
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Analysis 2.5. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome 5
Any functional impairment at 7 years of age..
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 5 Any functional impairment at 7 years of age.
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beta-lactam antibiotics alone vs no antibiotics
Kenyon 2001a 299/763 92/245 100.0 % 1.04 [ 0.87, 1.25 ]
Subtotal (95% CI) 763 245 100.0 % 1.04 [ 0.87, 1.25 ]
Total events: 299 (Antibiotics), 92 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
2 Macrolide antibiotics alone vs no antibiotics
Kenyon 2001a 333/785 92/245 100.0 % 1.13 [ 0.94, 1.35 ]
Subtotal (95% CI) 785 245 100.0 % 1.13 [ 0.94, 1.35 ]
Total events: 333 (Antibiotics), 92 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Kenyon 2001a 325/769 92/245 100.0 % 1.13 [ 0.94, 1.35 ]
Subtotal (95% CI) 769 245 100.0 % 1.13 [ 0.94, 1.35 ]
Total events: 325 (Antibiotics), 92 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
4 Antibiotics active against anaerobic bacteria vs no antibiotics
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antibiotics), 0 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.46, df = 2 (P = 0.80), I2 =0.0%
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Analysis 2.6. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome 6
Moderate/severe functional impairment at 7 years of age..
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 6 Moderate/severe functional impairment at 7 years of age.
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beta-lactam antibiotics alone vs no antibiotics
Kenyon 2001a 131/763 41/245 100.0 % 1.03 [ 0.75, 1.41 ]
Subtotal (95% CI) 763 245 100.0 % 1.03 [ 0.75, 1.41 ]
Total events: 131 (Antibiotics), 41 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
2 Macrolide antibiotics alone vs no antibiotics
Kenyon 2001a 142/785 41/245 100.0 % 1.08 [ 0.79, 1.48 ]
Subtotal (95% CI) 785 245 100.0 % 1.08 [ 0.79, 1.48 ]
Total events: 142 (Antibiotics), 41 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Kenyon 2001a 144/769 41/245 100.0 % 1.12 [ 0.82, 1.53 ]
Subtotal (95% CI) 769 245 100.0 % 1.12 [ 0.82, 1.53 ]
Total events: 144 (Antibiotics), 41 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
4 Antibiotics active against anaerobic bacteria vs no antibiotics
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antibiotics), 0 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.14, df = 2 (P = 0.93), I2 =0.0%
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Analysis 2.7. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome 7
Cerebral palsy at 7 years of age.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 7 Cerebral palsy at 7 years of age
Study or subgroup Antibiotics No antibiotics Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta-lactam antibiotics alone vs no antibiotics
Kenyon 2001a 15/792 4/257 100.0 % 1.22 [ 0.41, 3.63 ]
Subtotal (95% CI) 792 257 100.0 % 1.22 [ 0.41, 3.63 ]
Total events: 15 (Antibiotics), 4 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
2 Macrolide antibiotics alone vs no antibiotics
Kenyon 2001a 18/816 4/257 100.0 % 1.42 [ 0.48, 4.15 ]
Subtotal (95% CI) 816 257 100.0 % 1.42 [ 0.48, 4.15 ]
Total events: 18 (Antibiotics), 4 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Kenyon 2001a 35/795 4/257 100.0 % 2.83 [ 1.02, 7.88 ]
Subtotal (95% CI) 795 257 100.0 % 2.83 [ 1.02, 7.88 ]
Total events: 35 (Antibiotics), 4 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.047)
4 Antibiotics active against anaerobic bacteria vs no antibiotics
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antibiotics), 0 (No antibiotics)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 1.41, df = 2 (P = 0.49), I2 =0.0%
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Analysis 2.8. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome 8
Maternal adverse drug reaction requiring cessation of treatment.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 8 Maternal adverse drug reaction requiring cessation of treatment
Study or subgroup Antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beta-lactam antibiotics alone vs no antibiotics
Cox 1996 1/40 0/42 100.0 % 3.15 [ 0.13, 75.05 ]
Subtotal (95% CI) 40 42 100.0 % 3.15 [ 0.13, 75.05 ]
Total events: 1 (Antibiotic), 0 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
2 Macrolide antibiotics alone vs no antibiotics
McGregor 1991 15/53 16/50 100.0 % 0.88 [ 0.49, 1.59 ]
Subtotal (95% CI) 53 50 100.0 % 0.88 [ 0.49, 1.59 ]
Total events: 15 (Antibiotic), 16 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Romero 1993 27/131 20/144 81.6 % 1.48 [ 0.88, 2.52 ]
Watts 1994 7/30 4/26 18.4 % 1.52 [ 0.50, 4.60 ]
Subtotal (95% CI) 161 170 100.0 % 1.49 [ 0.93, 2.40 ]
Total events: 34 (Antibiotic), 24 (No antibiotic)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
4 Antibiotics active against anaerobic bacteria vs no antibiotics
McGregor 1991 15/53 16/50 93.9 % 0.88 [ 0.49, 1.59 ]
Svare 1997 4/59 1/51 6.1 % 3.46 [ 0.40, 29.95 ]
Subtotal (95% CI) 112 101 100.0 % 1.04 [ 0.59, 1.83 ]
Total events: 19 (Antibiotic), 17 (No antibiotic)
Heterogeneity: Chi2 = 1.48, df = 1 (P = 0.22); I2 =33%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 2.39, df = 3 (P = 0.50), I2 =0.0%
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Analysis 2.9. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome 9
Maternal infection.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 9 Maternal infection
Study or subgroup Antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta-lactam antibiotics alone vs no antibiotics
Gordon 1995 2/58 3/59 2.4 % 0.68 [ 0.12, 3.91 ]
Kenyon 2001a 141/1534 61/519 92.8 % 0.78 [ 0.59, 1.04 ]
Newton 1991 1/43 6/43 1.7 % 0.17 [ 0.02, 1.33 ]
Reimer 1999 2/61 6/68 3.1 % 0.37 [ 0.08, 1.77 ]
Subtotal (95% CI) 1696 689 100.0 % 0.74 [ 0.56, 0.97 ]
Total events: 146 (Antibiotic), 76 (No antibiotic)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.92, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.15 (P = 0.032)
2 Macrolide antibiotics alone vs no antibiotics
Kenyon 2001a 156/1600 61/519 98.5 % 0.83 [ 0.63, 1.10 ]
McGregor 1991 1/53 3/50 1.5 % 0.31 [ 0.03, 2.92 ]
Subtotal (95% CI) 1653 569 100.0 % 0.82 [ 0.62, 1.08 ]
Total events: 157 (Antibiotic), 64 (No antibiotic)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Kenyon 2001a 136/1551 61/519 58.7 % 0.75 [ 0.56, 0.99 ]
Oyarzun 1998 5/83 8/90 4.1 % 0.68 [ 0.23, 1.99 ]
Romero 1993 7/131 14/144 6.2 % 0.55 [ 0.23, 1.32 ]
Watts 1994 17/25 14/20 30.9 % 0.97 [ 0.66, 1.44 ]
Subtotal (95% CI) 1790 773 100.0 % 0.79 [ 0.64, 0.98 ]
Total events: 165 (Antibiotic), 97 (No antibiotic)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.19, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
4 Antibiotics active against anaerobic bacteria vs no antibiotics
McGregor 1991 1/53 3/50 37.0 % 0.31 [ 0.03, 2.92 ]
Norman 1994 1/43 3/38 37.1 % 0.29 [ 0.03, 2.71 ]
Svare 1997 3/59 0/51 25.9 % 6.07 [ 0.32, 114.74 ]
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(. . . Continued)
Study or subgroup Antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 155 139 100.0 % 0.66 [ 0.11, 3.92 ]
Total events: 5 (Antibiotic), 6 (No antibiotic)
Heterogeneity: Tau2 = 0.94; Chi2 = 3.22, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Chi2 = 0.29, df = 3 (P = 0.96), I2 =0.0%
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Analysis 2.10. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome
10 Birth within 48 hours of randomisation.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 10 Birth within 48 hours of randomisation
Study or subgroup Antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beta-lactam antibiotics alone vs no antibiotics
Kenyon 2001a 152/1534 51/519 100.0 % 1.01 [ 0.75, 1.36 ]
Subtotal (95% CI) 1534 519 100.0 % 1.01 [ 0.75, 1.36 ]
Total events: 152 (Antibiotic), 51 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
2 Macrolide antibiotics alone vs no antibiotics
Kenyon 2001a 166/1600 51/519 100.0 % 1.06 [ 0.78, 1.42 ]
Subtotal (95% CI) 1600 519 100.0 % 1.06 [ 0.78, 1.42 ]
Total events: 166 (Antibiotic), 51 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Kenyon 2001a 166/1551 51/519 77.6 % 1.09 [ 0.81, 1.47 ]
Oyarzun 1998 12/83 13/90 12.7 % 1.00 [ 0.48, 2.07 ]
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(. . . Continued)
Study or subgroup Antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Romero 1993 14/133 10/144 9.7 % 1.52 [ 0.70, 3.30 ]
Subtotal (95% CI) 1767 753 100.0 % 1.12 [ 0.86, 1.45 ]
Total events: 192 (Antibiotic), 74 (No antibiotic)
Heterogeneity: Chi2 = 0.71, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
4 Antibiotics active against anaerobic bacteria vs no antibiotics
Svare 1997 5/58 8/51 100.0 % 0.55 [ 0.19, 1.57 ]
Subtotal (95% CI) 58 51 100.0 % 0.55 [ 0.19, 1.57 ]
Total events: 5 (Antibiotic), 8 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi2 = 1.76, df = 3 (P = 0.62), I2 =0.0%
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Analysis 2.11. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome
11 Interval between randomisation and birth (days).
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 11 Interval between randomisation and birth (days)
Study or subgroup Antibiotcs No antibiotics
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Beta-lactam antibiotics alone vs no antibiotics
Kenyon 2001a 1534 43.99 (28.76) 519 44.08 (28.91) 100.0 % -0.09 [ -2.96, 2.78 ]
Subtotal (95% CI) 1534 519 100.0 % -0.09 [ -2.96, 2.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
2 Macrolide antibiotics alone vs no antibiotics
Kenyon 2001a 1600 43.05 (28.83) 519 44.08 (28.91) 41.8 % -1.03 [ -3.89, 1.83 ]
McGregor 1991 53 35.3 (24.1) 50 25.4 (20) 27.3 % 9.90 [ 1.37, 18.43 ]
Rajaei 2006 38 33.33 (18.36) 42 26.88 (13.9) 30.8 % 6.45 [ -0.74, 13.64 ]
Subtotal (95% CI) 1691 611 100.0 % 4.26 [ -2.88, 11.41 ]
Heterogeneity: Tau2 = 29.61; Chi2 = 8.31, df = 2 (P = 0.02); I2 =76%
Test for overall effect: Z = 1.17 (P = 0.24)
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Kenyon 2001a 1551 43.86 (29.29) 519 44.08 (28.91) 86.7 % -0.22 [ -3.10, 2.66 ]
Newton 1989 48 34.2 (21) 47 34.1 (24) 8.7 % 0.10 [ -8.98, 9.18 ]
Watts 1994 30 21.4 (22) 26 23.3 (25.3) 4.6 % -1.90 [ -14.41, 10.61 ]
Subtotal (95% CI) 1629 592 100.0 % -0.27 [ -2.95, 2.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
4 Antibiotics active against anaerobic bacteria vs no antibiotics
McGregor 1991 53 35.3 (24.1) 50 25.4 (20) 42.3 % 9.90 [ 1.37, 18.43 ]
Norman 1994 43 23.5 (24.2) 38 16 (22) 30.5 % 7.50 [ -2.56, 17.56 ]
Svare 1997 58 43.9 (30.7) 51 29.1 (26) 27.2 % 14.80 [ 4.15, 25.45 ]
Subtotal (95% CI) 154 139 100.0 % 10.50 [ 4.95, 16.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.99, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.71 (P = 0.00021)
Test for subgroup differences: Chi2 = 13.41, df = 3 (P = 0.00), I2 =78%
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Analysis 2.12. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome
12 Preterm birth (< 36 or < 37 weeks’ gestation).
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 12 Preterm birth (< 36 or < 37 weeks’ gestation)
Study or subgroup Antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beta-lactam antibiotics alone vs no antibiotics
Cox 1996 23/39 22/39 8.1 % 1.05 [ 0.71, 1.53 ]
Gordon 1995 35/58 34/59 12.8 % 1.05 [ 0.77, 1.42 ]
Kenyon 2001a 545/1534 186/519 65.8 % 0.99 [ 0.87, 1.13 ]
Keuchkerian 2005 17/47 19/49 4.4 % 0.93 [ 0.56, 1.57 ]
Newton 1991 23/43 27/43 9.0 % 0.85 [ 0.59, 1.22 ]
Subtotal (95% CI) 1721 709 100.0 % 0.99 [ 0.89, 1.10 ]
Total events: 643 (Antibiotic), 288 (No antibiotic)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 4 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
2 Macrolide antibiotics alone vs no antibiotics
Kenyon 2001a 584/1600 186/519 80.6 % 1.02 [ 0.89, 1.16 ]
McGregor 1991 38/58 37/58 19.4 % 1.03 [ 0.78, 1.34 ]
Subtotal (95% CI) 1658 577 100.0 % 1.02 [ 0.91, 1.15 ]
Total events: 622 (Antibiotic), 223 (No antibiotic)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Kenyon 2001a 558/1551 186/519 62.5 % 1.00 [ 0.88, 1.15 ]
Newton 1989 18/48 21/47 4.7 % 0.84 [ 0.52, 1.36 ]
Oyarzun 1998 38/83 45/90 11.3 % 0.92 [ 0.67, 1.25 ]
Romero 1993 69/131 74/144 21.4 % 1.02 [ 0.82, 1.29 ]
Subtotal (95% CI) 1813 800 100.0 % 0.99 [ 0.89, 1.10 ]
Total events: 683 (Antibiotic), 326 (No antibiotic)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.82, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
4 Antibiotics active against anaerobic bacteria vs no antibiotics
McGregor 1991 38/58 37/58 53.6 % 1.03 [ 0.78, 1.34 ]
Svare 1997 25/59 33/51 46.4 % 0.65 [ 0.46, 0.94 ]
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(. . . Continued)
Study or subgroup Antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 117 109 100.0 % 0.83 [ 0.53, 1.30 ]
Total events: 63 (Antibiotic), 70 (No antibiotic)
Heterogeneity: Tau2 = 0.08; Chi2 = 3.94, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Chi2 = 0.81, df = 3 (P = 0.85), I2 =0.0%
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Analysis 2.13. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome
13 Respiratory distress syndrome.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 13 Respiratory distress syndrome
Study or subgroup Antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beta-lactam antibiotics alone vs no antibiotics
Kenyon 2001a 127/1534 138/1556 89.4 % 0.93 [ 0.74, 1.18 ]
Keuchkerian 2005 3/47 3/49 1.9 % 1.04 [ 0.22, 4.91 ]
Newton 1991 12/47 13/45 8.7 % 0.88 [ 0.45, 1.73 ]
Subtotal (95% CI) 1628 1650 100.0 % 0.93 [ 0.75, 1.16 ]
Total events: 142 (Antibiotic), 154 (No antibiotic)
Heterogeneity: Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
2 Macrolide antibiotics alone vs no antibiotics
Kenyon 2001a 133/1600 138/1556 100.0 % 0.94 [ 0.75, 1.18 ]
Subtotal (95% CI) 1600 1556 100.0 % 0.94 [ 0.75, 1.18 ]
Total events: 133 (Antibiotic), 138 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
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(. . . Continued)
Study or subgroup Antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Kenyon 2001a 139/1551 138/1556 92.9 % 1.01 [ 0.81, 1.27 ]
Romero 1993 14/131 11/144 7.1 % 1.40 [ 0.66, 2.97 ]
Subtotal (95% CI) 1682 1700 100.0 % 1.04 [ 0.84, 1.29 ]
Total events: 153 (Antibiotic), 149 (No antibiotic)
Heterogeneity: Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
4 Antibiotics active against anaerobic bacteria vs no antibiotics
Svare 1997 2/58 3/51 100.0 % 0.59 [ 0.10, 3.37 ]
Subtotal (95% CI) 58 51 100.0 % 0.59 [ 0.10, 3.37 ]
Total events: 2 (Antibiotic), 3 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 0.92, df = 3 (P = 0.82), I2 =0.0%
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Analysis 2.14. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome
14 Necrotising enterocolitis.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 14 Necrotising enterocolitis
Study or subgroup Antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beta-lactam antibiotics alone vs no antibiotics
Cox 1996 0/40 1/42 17.3 % 0.35 [ 0.01, 8.34 ]
Kenyon 2001a 19/1534 4/519 70.6 % 1.61 [ 0.55, 4.70 ]
Newton 1991 1/47 1/45 12.1 % 0.96 [ 0.06, 14.85 ]
Subtotal (95% CI) 1621 606 100.0 % 1.31 [ 0.52, 3.32 ]
Total events: 20 (Antibiotic), 6 (No antibiotic)
Heterogeneity: Chi2 = 0.86, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
2 Macrolide antibiotics alone vs no antibiotics
Kenyon 2001a 16/1600 4/519 100.0 % 1.30 [ 0.44, 3.86 ]
Subtotal (95% CI) 1600 519 100.0 % 1.30 [ 0.44, 3.86 ]
Total events: 16 (Antibiotic), 4 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Kenyon 2001a 23/1551 4/519 55.7 % 1.92 [ 0.67, 5.54 ]
Romero 1993 3/131 5/144 44.3 % 0.66 [ 0.16, 2.71 ]
Subtotal (95% CI) 1682 663 100.0 % 1.36 [ 0.60, 3.11 ]
Total events: 26 (Antibiotic), 9 (No antibiotic)
Heterogeneity: Chi2 = 1.42, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.74 (P = 0.46)
4 Antibiotics active against anaerobic bacteria vs no antibiotics
Norman 1994 0/43 5/38 78.5 % 0.08 [ 0.00, 1.41 ]
Svare 1997 0/58 1/51 21.5 % 0.29 [ 0.01, 7.06 ]
Subtotal (95% CI) 101 89 100.0 % 0.13 [ 0.02, 1.01 ]
Total events: 0 (Antibiotic), 6 (No antibiotic)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Chi2 = 4.64, df = 3 (P = 0.20), I2 =35%
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Analysis 2.15. Comparison 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic), Outcome
15 Intraventricular haemorrhage.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 2 Antibiotics versus no antibiotics (subgrouped by type of antibiotic)
Outcome: 15 Intraventricular haemorrhage
Study or subgroup Antibiotic No antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beta-lactam antibiotics alone vs no antibiotics
Kenyon 2001a 17/1534 7/519 83.7 % 0.82 [ 0.34, 1.97 ]
Keuchkerian 2005 0/47 0/49 Not estimable
Newton 1991 2/47 2/45 16.3 % 0.96 [ 0.14, 6.51 ]
Subtotal (95% CI) 1628 613 100.0 % 0.84 [ 0.38, 1.87 ]
Total events: 19 (Antibiotic), 9 (No antibiotic)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
2 Macrolide antibiotics alone vs no antibiotics
Kenyon 2001a 18/1600 7/519 100.0 % 0.83 [ 0.35, 1.99 ]
Subtotal (95% CI) 1600 519 100.0 % 0.83 [ 0.35, 1.99 ]
Total events: 18 (Antibiotic), 7 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
3 Macrolide and beta-lactam antibiotics vs no antibiotics
Kenyon 2001a 20/1551 7/519 91.7 % 0.96 [ 0.41, 2.25 ]
Romero 1993 1/131 1/144 8.3 % 1.10 [ 0.07, 17.40 ]
Subtotal (95% CI) 1682 663 100.0 % 0.97 [ 0.43, 2.19 ]
Total events: 21 (Antibiotic), 8 (No antibiotic)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
4 Antibiotics active against anaerobic bacteria vs no antibiotics
Svare 1997 1/58 5/51 100.0 % 0.18 [ 0.02, 1.46 ]
Subtotal (95% CI) 58 51 100.0 % 0.18 [ 0.02, 1.46 ]
Total events: 1 (Antibiotic), 5 (No antibiotic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Chi2 = 2.20, df = 3 (P = 0.53), I2 =0.0%
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Analysis 3.1. Comparison 3 Any macrolide versus no macrolide, Outcome 1 Perinatal mortality.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 1 Perinatal mortality
Study or subgroup Any macrolide No macrolide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 90/3151 77/3090 97.6 % 1.15 [ 0.85, 1.55 ]
Oyarzun 1998 2/78 1/90 1.2 % 2.31 [ 0.21, 24.97 ]
Romero 1993 2/131 0/144 0.6 % 5.49 [ 0.27, 113.36 ]
Watts 1994 1/30 0/26 0.7 % 2.61 [ 0.11, 61.51 ]
Total (95% CI) 3390 3350 100.0 % 1.20 [ 0.89, 1.60 ]
Total events: 95 (Any macrolide), 78 (No macrolide)
Heterogeneity: Chi2 = 1.58, df = 3 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Any macrolide versus no macrolide, Outcome 2 Stillbirth.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 2 Stillbirth
Study or subgroup Any macrolide No macrolide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 23/3151 32/3090 100.0 % 0.70 [ 0.41, 1.20 ]
Romero 1993 0/133 0/144 Not estimable
Total (95% CI) 3284 3234 100.0 % 0.70 [ 0.41, 1.20 ]
Total events: 23 (Any macrolide), 32 (No macrolide)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours any macrolide Favours no macrolide
88Prophylactic antibiotics for inhibiting preterm labour with intact membranes (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.3. Comparison 3 Any macrolide versus no macrolide, Outcome 3 Neonatal death.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 3 Neonatal death
Study or subgroup Any macrolide No macrolide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 67/3151 45/3090 97.0 % 1.46 [ 1.00, 2.12 ]
Oyarzun 1998 2/78 1/90 2.0 % 2.31 [ 0.21, 24.97 ]
Romero 1993 2/131 0/144 1.0 % 5.49 [ 0.27, 113.36 ]
Total (95% CI) 3360 3324 100.0 % 1.52 [ 1.05, 2.19 ]
Total events: 71 (Any macrolide), 46 (No macrolide)
Heterogeneity: Chi2 = 0.85, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Any macrolide versus no macrolide, Outcome 4 Infant death.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 4 Infant death
Study or subgroup Any macrolide No macrolide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 61/2304 41/2279 100.0 % 1.47 [ 0.99, 2.18 ]
Total (95% CI) 2304 2279 100.0 % 1.47 [ 0.99, 2.18 ]
Total events: 61 (Any macrolide), 41 (No macrolide)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Any macrolide versus no macrolide, Outcome 5 Any functional impairment at 7
years of age..
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 5 Any functional impairment at 7 years of age.
Study or subgroup Any macrolide No macrolide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 658/1554 574/1498 100.0 % 1.11 [ 1.01, 1.20 ]
Total (95% CI) 1554 1498 100.0 % 1.11 [ 1.01, 1.20 ]
Total events: 658 (Any macrolide), 574 (No macrolide)
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Any macrolide versus no macrolide, Outcome 6 Moderate/severe functional
impairment at 7 years of age..
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 6 Moderate/severe functional impairment at 7 years of age.
Study or subgroup Any macrolide No macrolide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 286/1554 255/1498 100.0 % 1.08 [ 0.93, 1.26 ]
Total (95% CI) 1554 1498 100.0 % 1.08 [ 0.93, 1.26 ]
Total events: 286 (Any macrolide), 255 (No macrolide)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Any macrolide versus no macrolide, Outcome 7 Cerebral palsy at 7 years.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 7 Cerebral palsy at 7 years
Study or subgroup Any macrolide No macrolide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 53/1611 27/1562 100.0 % 1.90 [ 1.20, 3.01 ]
Total (95% CI) 1611 1562 100.0 % 1.90 [ 1.20, 3.01 ]
Total events: 53 (Any macrolide), 27 (No macrolide)
Heterogeneity: not applicable
Test for overall effect: Z = 2.75 (P = 0.0059)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Any macrolide versus no macrolide, Outcome 8 Maternal adverse drug
reaction requiring cessation of treatment.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 8 Maternal adverse drug reaction requiring cessation of treatment
Study or subgroup Any macrolide No macrolide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Romero 1993 27/131 20/144 81.6 % 1.48 [ 0.88, 2.52 ]
Watts 1994 7/30 4/26 18.4 % 1.52 [ 0.50, 4.60 ]
Total (95% CI) 161 170 100.0 % 1.49 [ 0.93, 2.40 ]
Total events: 34 (Any macrolide), 24 (No macrolide)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 Any macrolide versus no macrolide, Outcome 9 Maternal infection.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 9 Maternal infection
Study or subgroup Any macrolide No macrolide Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kenyon 2001a 292/3151 324/3090 53.1 % 0.88 [ 0.76, 1.03 ]
Oyarzun 1998 5/83 8/90 14.6 % 0.68 [ 0.23, 1.99 ]
Romero 1993 7/131 14/144 19.5 % 0.55 [ 0.23, 1.32 ]
Watts 1994 3/30 10/26 12.8 % 0.26 [ 0.08, 0.84 ]
Total (95% CI) 3395 3350 100.0 % 0.66 [ 0.41, 1.07 ]
Total events: 307 (Any macrolide), 356 (No macrolide)
Heterogeneity: Tau2 = 0.11; Chi2 = 5.26, df = 3 (P = 0.15); I2 =43%
Test for overall effect: Z = 1.68 (P = 0.093)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 Any macrolide versus no macrolide, Outcome 10 Birth within 48 hours of
randomisation.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 10 Birth within 48 hours of randomisation
Study or subgroup Any macrolide No macrolide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 332/3151 304/3090 93.3 % 1.07 [ 0.92, 1.24 ]
Oyarzun 1998 12/83 13/90 3.8 % 1.00 [ 0.48, 2.07 ]
Romero 1993 14/133 10/144 2.9 % 1.52 [ 0.70, 3.30 ]
Total (95% CI) 3367 3324 100.0 % 1.08 [ 0.94, 1.25 ]
Total events: 358 (Any macrolide), 327 (No macrolide)
Heterogeneity: Chi2 = 0.79, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 Any macrolide versus no macrolide, Outcome 11 Interval between
randomisation and birth (days).
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 11 Interval between randomisation and birth (days)
Study or subgroup Any macrolide No macrolide
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kenyon 2001a 3151 43.45 (29.06) 3099 44.04 (28.03) 62.8 % -0.59 [ -2.01, 0.83 ]
Rajaei 2006 38 33.33 (18.36) 42 26.88 (13.9) 25.7 % 6.45 [ -0.74, 13.64 ]
Watts 1994 30 21.4 (22) 26 23.3 (25.3) 11.5 % -1.90 [ -14.41, 10.61 ]
Total (95% CI) 3219 3167 100.0 % 1.07 [ -3.58, 5.72 ]
Heterogeneity: Tau2 = 8.45; Chi2 = 3.60, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 3.12. Comparison 3 Any macrolide versus no macrolide, Outcome 12 Preterm birth (< 36 or < 37
weeks).
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 12 Preterm birth (< 36 or < 37 weeks)
Study or subgroup Any macrolide No macrolide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 1142/3151 1104/3090 89.2 % 1.01 [ 0.95, 1.08 ]
Newton 1989 18/48 21/47 1.7 % 0.84 [ 0.52, 1.36 ]
Oyarzun 1998 38/83 45/90 3.5 % 0.92 [ 0.67, 1.25 ]
Romero 1993 69/131 74/144 5.6 % 1.02 [ 0.82, 1.29 ]
Total (95% CI) 3413 3371 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 1267 (Any macrolide), 1244 (No macrolide)
Heterogeneity: Chi2 = 0.97, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 3.13. Comparison 3 Any macrolide versus no macrolide, Outcome 13 Respiratory distress
syndrome.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 13 Respiratory distress syndrome
Study or subgroup Any macrolide No macrolide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 272/3151 265/3090 91.3 % 1.01 [ 0.86, 1.18 ]
Oyarzun 1998 9/78 7/90 2.2 % 1.48 [ 0.58, 3.80 ]
Romero 1993 14/131 11/144 3.6 % 1.40 [ 0.66, 2.97 ]
Watts 1994 13/30 8/26 2.9 % 1.41 [ 0.69, 2.86 ]
Total (95% CI) 3390 3350 100.0 % 1.04 [ 0.90, 1.21 ]
Total events: 308 (Any macrolide), 291 (No macrolide)
Heterogeneity: Chi2 = 2.00, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 3.14. Comparison 3 Any macrolide versus no macrolide, Outcome 14 Intraventricular
haemorrhage.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 14 Intraventricular haemorrhage
Study or subgroup Any macrolide No macrolide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 38/3151 39/3090 97.6 % 0.96 [ 0.61, 1.49 ]
Romero 1993 1/131 1/144 2.4 % 1.10 [ 0.07, 17.40 ]
Total (95% CI) 3282 3234 100.0 % 0.96 [ 0.62, 1.49 ]
Total events: 39 (Any macrolide), 40 (No macrolide)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 3.15. Comparison 3 Any macrolide versus no macrolide, Outcome 15 Necrotising enterocolitis.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 3 Any macrolide versus no macrolide
Outcome: 15 Necrotising enterocolitis
Study or subgroup Any macrolide No macrolide Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 39/3151 31/3090 86.8 % 1.23 [ 0.77, 1.97 ]
Romero 1993 3/131 5/144 13.2 % 0.66 [ 0.16, 2.71 ]
Total (95% CI) 3282 3234 100.0 % 1.16 [ 0.74, 1.80 ]
Total events: 42 (Any macrolide), 36 (No macrolide)
Heterogeneity: Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 1 Perinatal mortality.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 1 Perinatal mortality
Study or subgroup Any beta-lactam No beta-lactam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1996 1/40 0/42 0.6 % 3.15 [ 0.13, 75.05 ]
Kenyon 2001a 85/3085 82/3156 93.6 % 1.06 [ 0.79, 1.43 ]
Keuchkerian 2005 1/47 1/49 1.1 % 1.04 [ 0.07, 16.19 ]
Norman 1994 2/43 2/38 2.5 % 0.88 [ 0.13, 5.97 ]
Oyarzun 1998 2/78 1/90 1.1 % 2.31 [ 0.21, 24.97 ]
Romero 1993 2/131 0/144 0.6 % 5.49 [ 0.27, 113.36 ]
Svare 1997 0/59 0/51 Not estimable
Watts 1994 1/30 0/26 0.6 % 2.61 [ 0.11, 61.51 ]
Total (95% CI) 3513 3596 100.0 % 1.12 [ 0.84, 1.48 ]
Total events: 94 (Any beta-lactam), 86 (No beta-lactam)
Heterogeneity: Chi2 = 2.28, df = 6 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 2 Stillbirth.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 2 Stillbirth
Study or subgroup Any beta-lactam No beta-lactam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1996 0/40 0/42 Not estimable
Kenyon 2001a 58/3085 54/3156 98.2 % 1.10 [ 0.76, 1.59 ]
Keuchkerian 2005 1/47 1/49 1.8 % 1.04 [ 0.07, 16.19 ]
Norman 1994 0/43 0/38 Not estimable
Romero 1993 0/133 0/144 Not estimable
Svare 1997 0/59 0/51 Not estimable
Total (95% CI) 3407 3480 100.0 % 1.10 [ 0.76, 1.58 ]
Total events: 59 (Any beta-lactam), 55 (No beta-lactam)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 3 Neonatal death.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 3 Neonatal death
Study or subgroup Any beta-lactam No beta-lactam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1996 1/40 0/42 1.0 % 3.15 [ 0.13, 75.05 ]
Kenyon 2001a 67/3151 45/3090 91.9 % 1.46 [ 1.00, 2.12 ]
Keuchkerian 2005 0/47 0/49 Not estimable
Norman 1994 2/43 2/38 4.3 % 0.88 [ 0.13, 5.97 ]
Oyarzun 1998 2/78 1/90 1.9 % 2.31 [ 0.21, 24.97 ]
Romero 1993 2/131 0/144 1.0 % 5.49 [ 0.27, 113.36 ]
Svare 1997 0/59 0/51 Not estimable
Total (95% CI) 3549 3504 100.0 % 1.51 [ 1.06, 2.15 ]
Total events: 74 (Any beta-lactam), 48 (No beta-lactam)
Heterogeneity: Chi2 = 1.36, df = 4 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 4 Infant death.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 4 Infant death
Study or subgroup Any beta-lactam No beta-lactam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 49/2304 53/2350 100.0 % 0.94 [ 0.64, 1.38 ]
Total (95% CI) 2304 2350 100.0 % 0.94 [ 0.64, 1.38 ]
Total events: 49 (Any beta-lactam), 53 (No beta-lactam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 5 Any functional impairment
at 7 years of age..
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 5 Any functional impairment at 7 years of age.
Study or subgroup Any beta-lactam No beta-lactam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 624/1532 608/1520 100.0 % 1.02 [ 0.93, 1.11 ]
Total (95% CI) 1532 1520 100.0 % 1.02 [ 0.93, 1.11 ]
Total events: 624 (Any beta-lactam), 608 (No beta-lactam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 6 Moderate/severe functional
impairment at 7 years of age..
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 6 Moderate/severe functional impairment at 7 years of age.
Study or subgroup Any beta-lactam No beta-lactam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 275/1532 266/1520 100.0 % 1.03 [ 0.88, 1.20 ]
Total (95% CI) 1532 1520 100.0 % 1.03 [ 0.88, 1.20 ]
Total events: 275 (Any beta-lactam), 266 (No beta-lactam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 7 Cerebral palsy at 7 years.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 7 Cerebral palsy at 7 years
Study or subgroup Any beta-lactam No beta-lactam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 50/1587 30/1586 100.0 % 1.67 [ 1.06, 2.61 ]
Total (95% CI) 1587 1586 100.0 % 1.67 [ 1.06, 2.61 ]
Total events: 50 (Any beta-lactam), 30 (No beta-lactam)
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 8 Maternal adverse drug
reaction requiring cessation of treatment.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 8 Maternal adverse drug reaction requiring cessation of treatment
Study or subgroup Any beta-lactam No beta-lactam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1996 1/40 0/42 2.0 % 3.15 [ 0.13, 75.05 ]
Romero 1993 27/131 20/144 76.5 % 1.48 [ 0.88, 2.52 ]
Svare 1997 4/59 1/51 4.3 % 3.46 [ 0.40, 29.95 ]
Watts 1994 7/30 4/26 17.2 % 1.52 [ 0.50, 4.60 ]
Total (95% CI) 260 263 100.0 % 1.61 [ 1.02, 2.54 ]
Total events: 39 (Any beta-lactam), 25 (No beta-lactam)
Heterogeneity: Chi2 = 0.75, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.043)
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 9 Maternal infection.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 9 Maternal infection
Study or subgroup Any beta-lactam No beta-lactam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gordon 1995 2/58 3/59 0.8 % 0.68 [ 0.12, 3.91 ]
Kenyon 2001a 277/3085 339/3156 88.4 % 0.84 [ 0.72, 0.97 ]
Norman 1994 1/43 3/38 0.8 % 0.29 [ 0.03, 2.71 ]
Oyarzun 1998 5/83 8/90 2.0 % 0.68 [ 0.23, 1.99 ]
Reimer 1999 2/61 6/68 1.5 % 0.37 [ 0.08, 1.77 ]
Romero 1993 7/131 14/144 3.5 % 0.55 [ 0.23, 1.32 ]
Svare 1997 3/59 0/51 0.1 % 6.07 [ 0.32, 114.74 ]
Watts 1994 3/30 10/26 2.8 % 0.26 [ 0.08, 0.84 ]
Total (95% CI) 3550 3632 100.0 % 0.80 [ 0.69, 0.92 ]
Total events: 300 (Any beta-lactam), 383 (No beta-lactam)
Heterogeneity: Chi2 = 8.18, df = 7 (P = 0.32); I2 =14%
Test for overall effect: Z = 3.03 (P = 0.0025)
Test for subgroup differences: Not applicable
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Analysis 4.10. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 10 Birth within 48 hours of
randomisation.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 10 Birth within 48 hours of randomisation
Study or subgroup Any beta-lactam No beta-lactam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 318/3085 318/3156 91.1 % 1.02 [ 0.88, 1.19 ]
Oyarzun 1998 12/83 13/90 3.6 % 1.00 [ 0.48, 2.07 ]
Romero 1993 14/133 10/144 2.8 % 1.52 [ 0.70, 3.30 ]
Svare 1997 5/58 8/51 2.5 % 0.55 [ 0.19, 1.57 ]
Total (95% CI) 3359 3441 100.0 % 1.02 [ 0.89, 1.18 ]
Total events: 349 (Any beta-lactam), 349 (No beta-lactam)
Heterogeneity: Chi2 = 2.33, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 4.11. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 11 Interval between
randomisation and birth (days).
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 11 Interval between randomisation and birth (days)
Study or subgroup Any beta-lactam No beta-lactam
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kenyon 2001a 3065 43.93 (29.02) 3156 43.56 (28.87) 46.8 % 0.37 [ -1.07, 1.81 ]
Svare 1997 58 43.9 (30.7) 51 29.1 (26) 28.5 % 14.80 [ 4.15, 25.45 ]
Watts 1994 30 21.4 (22) 26 23.3 (25.3) 24.7 % -1.90 [ -14.41, 10.61 ]
Total (95% CI) 3153 3233 100.0 % 3.92 [ -5.08, 12.92 ]
Heterogeneity: Tau2 = 44.55; Chi2 = 7.09, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 4.12. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 12 Preterm birth (< 36 or <
37 weeks).
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 12 Preterm birth (< 36 or < 37 weeks)
Study or subgroup Any beta-lactam No beta-lactam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1996 23/39 22/39 1.6 % 1.05 [ 0.71, 1.53 ]
Gordon 1995 35/58 34/59 2.5 % 1.05 [ 0.77, 1.42 ]
Kenyon 2001a 1103/3085 1143/3156 82.2 % 0.99 [ 0.92, 1.05 ]
Keuchkerian 2005 17/47 19/49 1.4 % 0.93 [ 0.56, 1.57 ]
Newton 1989 18/48 21/47 1.5 % 0.84 [ 0.52, 1.36 ]
Oyarzun 1998 38/83 45/90 3.1 % 0.92 [ 0.67, 1.25 ]
Romero 1993 69/131 74/144 5.1 % 1.02 [ 0.82, 1.29 ]
Svare 1997 25/59 33/51 2.6 % 0.65 [ 0.46, 0.94 ]
Total (95% CI) 3550 3635 100.0 % 0.98 [ 0.92, 1.04 ]
Total events: 1328 (Any beta-lactam), 1391 (No beta-lactam)
Heterogeneity: Chi2 = 5.91, df = 7 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 4.13. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 13 Respiratory distress
syndrome.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 13 Respiratory distress syndrome
Study or subgroup Any beta-lactam No beta-lactam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1996 8/40 8/42 2.5 % 1.05 [ 0.44, 2.53 ]
Kenyon 2001a 266/3085 271/3156 85.4 % 1.00 [ 0.85, 1.18 ]
Keuchkerian 2005 3/47 3/49 0.9 % 1.04 [ 0.22, 4.91 ]
Norman 1994 3/43 6/38 2.0 % 0.44 [ 0.12, 1.65 ]
Oyarzun 1998 9/78 7/90 2.1 % 1.48 [ 0.58, 3.80 ]
Romero 1993 14/131 11/144 3.3 % 1.40 [ 0.66, 2.97 ]
Svare 1997 2/58 3/51 1.0 % 0.59 [ 0.10, 3.37 ]
Watts 1994 13/30 8/26 2.7 % 1.41 [ 0.69, 2.86 ]
Total (95% CI) 3512 3596 100.0 % 1.02 [ 0.88, 1.19 ]
Total events: 318 (Any beta-lactam), 317 (No beta-lactam)
Heterogeneity: Chi2 = 4.06, df = 7 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 4.14. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 14 Intraventricular
haemorrhage.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 14 Intraventricular haemorrhage
Study or subgroup Any beta-lactam No beta-lactam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kenyon 2001a 37/3085 40/3156 86.3 % 0.95 [ 0.61, 1.48 ]
Keuchkerian 2005 0/47 0/49 Not estimable
Romero 1993 1/131 1/144 2.1 % 1.10 [ 0.07, 17.40 ]
Svare 1997 1/58 5/51 11.6 % 0.18 [ 0.02, 1.46 ]
Total (95% CI) 3321 3400 100.0 % 0.86 [ 0.56, 1.31 ]
Total events: 39 (Any beta-lactam), 46 (No beta-lactam)
Heterogeneity: Chi2 = 2.37, df = 2 (P = 0.31); I2 =16%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 4.15. Comparison 4 Any beta-lactam versus no beta-lactam, Outcome 15 Necrotising enterocolitis.
Review: Prophylactic antibiotics for inhibiting preterm labour with intact membranes
Comparison: 4 Any beta-lactam versus no beta-lactam
Outcome: 15 Necrotising enterocolitis
Study or subgroup Any beta-lactam No beta-lactam Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cox 1996 0/40 1/42 8.2 % 0.35 [ 0.01, 8.34 ]
Kenyon 2001a 42/3085 28/3156 48.3 % 1.53 [ 0.95, 2.47 ]
Norman 1994 0/43 5/38 9.7 % 0.08 [ 0.00, 1.41 ]
Romero 1993 3/131 5/144 25.7 % 0.66 [ 0.16, 2.71 ]
Svare 1997 0/58 1/51 8.2 % 0.29 [ 0.01, 7.06 ]
Total (95% CI) 3357 3431 100.0 % 0.72 [ 0.27, 1.92 ]
Total events: 45 (Any beta-lactam), 40 (No beta-lactam)
Heterogeneity: Tau2 = 0.46; Chi2 = 6.60, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Methods used to assess trials included in previous versions of this review
The standard methods of The Cochrane Collaboration were used as described in the Cochrane Reviewers’ Handbook (Clarke 2001).
Trials under consideration were evaluated for appropriateness for inclusion and methodological quality without consideration of their
results. The review authors independently applied the inclusion criteria to all potentially eligible trials and, for all included trials,
independently evaluated methodological quality and extracted data. Differences in interpretation were resolved by discussion.
Methods used for assessing trial quality:
Six major sources of potential bias and methods of avoidance of these biases were considered when assessing trial quality as follows.
1. Random sequence generation (selection bias)
2. Allocation concealment (selection bias)
3. Blinding (performance bias and detection bias)
4. Incomplete outcome data (attrition bias)
5. Selective reporting (reporting bias)
6. Other bias
The quality assessment rating for bias was:
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1. low risk
2. unclear risk
3. high risk
Data collection and analysis:
Trial data were extracted by the two review authors independently. Missing or incomplete data were sought in all cases from the trial
authors and included in the results where possible. Additional information was sought from investigators of the included study (Reimer
1999) and additional information from 2 trials (Kenyon 2008a; Gurbuz 2004). For further details, see table of ’Characteristics of
included studies’ and ’Characteristics of excluded studies’.
Analyses were conducted using a fixed-effect model. However, in the overall analysis two outcomes were noted to have statistically
significant heterogeneity: ’Admission to neonatal intensive care’ and, ’Interval from randomisation to delivery (days)’. On visual
inspection of the graph and subsequent sensitivity analyses, it appeared that the source of heterogeneity was the trials which used
antibiotics active against anaerobic organisms. Based on the results of sensitivity analyses by type of antibiotic (excluding trial using
antibiotics active against anaerobic antibiotics and also by random-effects versus fixed-effect models), it was decided the outcome of
’Interval from randomisation to delivery (days)’ would not be combined in an overall analysis as this summary statistic would be
potentially misleading. However, the outcome of ’Admission to neonatal intensive care’ was included using a random-effects model as
the results for this outcome were similar to that of the sensitivity analysis by type of antibiotic used.
Subgroup analyses were performed by type of antibiotic used as follows:
• treatment with macrolide antibiotics alone;
• treatment with beta-lactam antibiotics alone;
• treatment with macrolide and beta-lactam antibiotics;
• treatment with antibiotics active against anaerobic bacteria.
To avoid unit of analysis problems, data from the Kenyon 2001a (which employed a factorial design - three antibiotic arms and one
placebo) were included in these subgroup analyses following an adjustment to the placebo group. In these subgroup analyses, each
of the antibiotic arms from this trial were compared to the same placebo group (three comparisons). Therefore, the numerator and
denominator for all reported outcomes in the placebo arm were divided by three for categorical data and for outcomes reported on
a continuous scale dividing the denominators only by three. A sensitivity analysis comparing the results of the unadjusted with the
adjusted analyses demonstrated only minimal differences for all reported outcomes.
Results are presented using relative risk (RR) for categorical data and weighted mean difference (WMD) for variables measured on a
continuous scale and include 95 per cent confidence intervals (CI). Results are also expressed using number needed to treat (NNT)
where appropriate.
Appendix 2. Electronic Search Methods
The Cochrane Pregnancy and Childbirth Group will conduct a further search on submission of the update. The Trials Register is
maintained by the Trials Search Co-ordinator and contains trials identified from:
1. quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of EMBASE;
4. handsearches of 30 journals and the proceedings of major conferences;
5. weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL,MEDLINE and EMBASE, the list of handsearched journals and conference proceedings,
and the list of journals reviewed via the current awareness service can be found in the ‘Specialized Register’ section within the editorial
information about the Cochrane Pregnancy and Childbirth Group.
Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-
ordinator searches the register for each review using the topic list rather than keywords.
In addition, a search including the electronic databases: MEDLINE (1965 to Mar 2012), using text terms: antibiotic*, preterm,
prematur*, labour, labor, infection, amnionitis, chorioamnionitis. A manual search of the references of all retrieved articles will be
performed.
No language restrictions will be applied.
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WH A T ’ S N E W
Last assessed as up-to-date: 3 October 2013.
Date Event Description
3 October 2013 New citation required and conclusions have changed Conclusions changed, as described.
3 October 2013 New search has been performed This update includes an additional three studies (
Keuchkerian 2005; Rajaei 2006; Reimer 1999) including
305 women giving a total of 14 studies and 7837 women
now included in this review
In this update, an increase in neonatal deaths was shown
for infants of women allocated to receive any prophylactic
antibiotics. Follow-up data at seven years of age from the
UK children whose mothers joined ORACLE II trial (
Kenyon 2001a) showed the prescription of a macrolide
antibiotic (erythromycin) was associated with an increase
in functional impairment. The risk of cerebral palsy was
also increased with the use of antibiotics
An increase in maternal adverse drug reaction was shown
in women receiving any macrolide (erythromycin alone
or in combination with beta-lactams) antibiotics
The conclusions of the review are changed. This evi-
dence supports not giving antibiotics towomen in preterm
labour with intact membranes in the absence of signs of
infection
H I S T O R Y
Protocol first published: Issue 2, 1997
Review first published: Issue 1, 1998
Date Event Description
30 April 2010 Amended Search updated. Twelve reports added to Studies awaiting
classification
21 August 2008 Amended Converted to new review format.
20 August 2002 New search has been performed New search conducted.
20 August 2002 New citation required and conclusions have changed This review updates the King 2002.
In this update, the title has been changed to ’Prophylactic
antibiotics for inhibiting preterm labour with intactmem-
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(Continued)
branes’ to clarify the focus of the review. Also in this up-
date, changes have been made to the descriptions of some
outcomes measures and subgroup analyses as follows:
Several additional important neonatal outcomes have
been included.
Subgroup analyses by type of antibiotics have been mod-
ified to enhance clinical relevance as follows:
1. ’Single antibiotic therapy versus no antibiotics’ - de-
scription changed to ’Macrolide antibiotics versus no an-
tibiotics’.
2. ’Combination antibiotics therapy versus no antibiotics’
- description changed to ’Macrolide and beta-lactam an-
tibiotics versus no antibiotics’.
These changes are indicated by * in the review.
This update includes the addition of data from theKenyon
2001a trial. The earlier version of this review contained
data for the outcomes of 1187 women. With the inclu-
sion of the Kenyon 2001a trial, this review now contains
outcomes for 7428 women.
The earlier version indicated some maternal and neona-
tal benefits (less maternal and neonatal infection, some
prolongation of pregnancy) and a concern about in-
creased perinatal mortality. With the inclusion of data
from Kenyon 2001a in this update, these ’benefits’ (with
the exception of reducedmaternal infection) are no longer
apparent, but there is a concern about a trend towards
increased neonatal mortality
C O N T R I B U T I O N S O F A U T H O R S
Vicki Flenady compiled the review in consultation with co-authors. Glenda Halwey worked with Vicki Flenady to assess studies for
inclusion and extract data. Owen Stock extracted information on the new studies for this update, assisted in interpretation of the
results and editing the review. Nadia Badawi assisted with interpretation of the results. Sara Kenyon provided information on study
characteristics of the ORACLE trial and follow-up study, assisted in interpretation of the findings and editing the review. All authors
commented on drafts of the review and approved the final version before submission.
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D E C L A R A T I O N S O F I N T E R E S T
Sara Kenyon led the ORACLE trial and was the CI for the ORACLE Children’s Study.
S O U R C E S O F S U P P O R T
Internal sources
• Department of Perinatal Medicine, Royal Women’s Hospital, Melbourne, Victoria, Australia.
• Mater Medical Research Institute, Sth Brisbane, Queensland, Australia.
External sources
• Commonwealth Department of Health and Ageing, Canberra, Australian Capital Territory, Australia.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In this update October 2013, primary and secondary outcomes have been defined. Additional outcomes measures are included as
primary outcomes. These are: serious maternal adverse outcome related to antibiotic treatment (respiratory arrest, cardiac arrest, death)
and a composite measure of death (fetal, neonatal, or later death up to the time of follow-up) or major long-term infant neurosensory
impairment. Further, the list of outcomes measures included in subgroup analyses are now restricted to those which are considered to
be most clinically important. Two additional comparisons were included: Any macrolide antibiotics versus No macrolide antibiotics;
and Any beta-lactam antibiotics versus No beta-lactam antibiotics. We also removed the exclusion criterion according to attrition rates.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Bacterial Agents [adverse effects; therapeutic use]; Antibiotic Prophylaxis [adverse effects; ∗methods]; Macrolides [adverse effects;
therapeutic use]; Obstetric Labor, Premature [∗prevention & control]; Perinatal Mortality; Pregnancy Complications, Infectious [drug
therapy]; Randomized Controlled Trials as Topic; beta-Lactams [adverse effects; therapeutic use]
MeSH check words
Female; Humans; Pregnancy
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